

The contribution of de novo coding mutations to meningocele

Yoo-Jin Ha^{1,2,3}, Isaac Tang^{1,2}, Ashna Nisal^{1,2}, Ishani Jhamb^{1,2}, Cassidy Wallace^{1,2}, Sarah Schroeder^{1,2}, Chanjae Lee⁴, Keng loi Vong^{1,2}, Naomi Meave^{1,2}, Fiza Jiwani^{1,2}, Chelsea Barrows^{1,2}, Sangmoon Lee^{1,2}, Nan Jiang^{1,2}, Arzoo Patel^{1,2}, Francisco A. Blanco⁵, Seyoung Yu⁶, Hui Su Jeong^{1,2,7}, Isaac Plutzer⁸, Michael B. Major⁸, Béatrice Benoit⁹, Christian Poüs^{9,10}, Caleb Heffner¹¹, Zoha Kibar¹², Gyang Markus Bot¹³, Hope Northrup¹⁴, Kit Sing Au¹⁴, Madison Strain¹⁵, Allison Ashley-Koch¹⁵, Richard H. Finnell¹⁶, Joan T. Le¹⁷, Hal Meltzer¹⁷, Camila Araujo¹⁸, Helio R. Machado¹⁸, Roger E. Stevenson¹⁹, Anna Yurrita²⁰, Sara Mumtaz²¹, Osvaldo M. Mutchinick²², José Ramón Medina-Bereciartu²³, Friedhelm Hildebrandt²⁴, Gia Melikishvili²⁵, Rony Marwan²⁶, Valeria Capra²⁷, Mahmoud M. Nourdeen²⁸, Aida M.S. Salem²⁸, Mahmoud Y. Issa²⁹, Maha S. Zaki²⁹, Ji Eun Lee⁷, Anna Alkelai³⁰, Alan R. Shuldiner³⁰, Stephen F. Kingsmore¹, Stephen A. Murray¹¹, Heon Yung Gee⁶, W. Todd Miller^{31,32}, Kimberley F. Tolias⁵, John B. Wallingford⁴, Spina Bifida Sequencing Consortium*[^], Sangwoo Kim^{3, #}, Joseph G. Gleeson^{1,2, #[^]}

¹ Rady Children's Institute for Genomic Medicine, San Diego, CA 92123, USA

² Department of Neurosciences and Pediatrics, University of California, San Diego, CA 92037, USA

³ Department of Biomedical Systems Informatics and Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

⁴ Dept. of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA

⁵ Dept. Neuroscience, Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA

⁶ Department of Pharmacology and Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

⁷ Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Republic of Korea

⁸ Department of Cell Biology and Physiology, Washington University in St. Louis, MO 63110

⁹ INSERM UMR-S 1193, UFR de Pharmacie, University Paris-Saclay, UFR de Pharmacie, Orsay 91400, France.

¹⁰ Biochimie-Hormonologie, Assistance Publique - Hôpitaux de Paris Université Paris-Saclay, Clamart 92140, France

¹¹ The Jackson Laboratory, Bar Harbor, ME 04609, USA

¹² Department of Neurosciences, Research Center of CHU Sainte Justine, University of Montreal, Montreal, H3T 1C5, Canada

¹³ Neurosurgery Division, Department of Surgery, Jos University Teaching Hospital, Jos 930103, Nigeria

¹⁴ Department of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston and Children's Memorial Hermann Hospital, Houston, TX 77030, USA

¹⁵ Molecular Physiology Institute, Duke University Medical Center, Durham, NC 27710, USA

¹⁶ Center for Precision Environmental Health, Departments of Molecular and Human Genetics, Molecular and Cellular Biology and Medicine, Baylor College of Medicine, Houston 77030, TX, USA

¹⁷ Rady Children's Hospital, San Diego, CA 92123, USA

49 ¹⁸ Department of Surgery and Anatomy Ribeirão Preto Medical School University of São Paulo,
50 Ribeirao Preto SP 14015-068, Brazil

51 ¹⁹ J.C. Self Research Institute of Human Genetics, Greenwood Genetic Center, Greenwood, SC
52 29646, USA

53 ²⁰ Catedrática de Ciencias Ómicas, Facultad de Medicina, Universidad Francisco Marroquín,
54 01001, Guatemala

55 ²¹ National University of Medical Sciences, Rawalpindi 44000, Pakistan

56 ²² Department of Genetics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
57 Mexico City 14080, Mexico

58 ²³ Clínica Santa Sofia, Caracas 1061, Venezuela

59 ²⁴ Division of Nephrology, Boston Children's Hospital, Boston, MA 02115, USA

60 ²⁵ Department of Pediatrics, MediClubGeorgia Medical Center, Tbilisi, 0160, Georgia

61 ²⁶ Division of Pediatric Surgery, University of Colorado School of Medicine, Children's Hospital
62 of Colorado, Colorado Fetal Care Center, Aurora, CO, 80045, USA

63 ²⁷ Genomics and Clinical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa 16147, Italy

64 ²⁸ Department of Pediatrics, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt

65 ²⁹ Clinical Genetics Department, Human Genetics and Genome Research Division, National
66 Research Centre, Cairo 12311, Egypt

67 ³⁰ Regeneron Genetics Center, Tarrytown, NY 10591, USA

68 ³¹ Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY 11794,
69 USA

70 ³² VA Medical Center, Northport, NY 11768, USA

71

72 # Co-corresponding authors

73 *Consortium membership in appendix

74 ^ Contact PI for consortium: Joseph G. Gleeson

75 Keywords: Meningomyelocele, spina bifida, neural tube defect, de novo mutation, penetrance,
76 expressivity, trio, exome, protein-interaction network, congenital, hydrocephalus.

77 Abstract word count: 158

78 Text word Count: 2877

79 Number of Figures: 4

80 Number of Tables: 1

81 Number of Supplementary Figures: 16

82

83

84 **Abstract**

85 Meningocele (MM) is considered a genetically complex disease resulting from
86 failure of neural tube closure (NTD). Patients display neuromotor disability and frequent
87 hydrocephalus requiring ventricular shunting. A few proposed genes contribute to disease
88 susceptibility, but most risk remains unexplained¹. We postulated that de novo mutations
89 (DNMs) under purifying selection contribute to MM risk². Here we recruited a cohort of
90 851 MM trios requiring shunting at birth, compared with 732 control trios, and found that
91 de novo likely gene disrupting or damaging missense mutations occur in approximately
92 22.3% of subjects, 28% of which are estimated to contribute to disease risk. The 187
93 genes with damaging DNMs collectively define networks including actin cytoskeleton
94 and microtubule-based processes, axon guidance, and histone modification. Gene
95 validation demonstrates partial or complete loss of function, impaired signaling and
96 defective neural tube closure in *Xenopus* embryos. Our results suggest DNMs make key
97 contributions to MM risk, and highlight critical pathways required for neural tube closure
98 in human embryogenesis.
99

100 **Main**

101 MM, also known as spina bifida, is the most common central nervous system
102 (CNS) structural defect in humans. MM results from failed closure of the neural tube in
103 the first six weeks of gestation. While folic acid supplementation has reduced disease
104 burden³, the incidence of 1:3000–10,000 live-births, along with the associated lifelong
105 neuromotor disability and increased mortality, has focused attention on this condition.
106 Timely diagnosis allows for prenatal counseling and informed management choices,
107 including termination of pregnancy, fetal surgery, or postnatal surgery for the nearly fully
108 concordant hydrocephalus accompanying the hindbrain Chiari type II malformation^{4,5}.
109 Over 20 million people worldwide live with an NTD yet causes remain poorly defined.

110 Mouse knockout studies established hundreds of genes associated with NTD,
111 often with partial penetrance, implicating apical-basal polarity, Wnt/PCP, Wnt/beta-
112 catenin, and DNA transcription pathways⁶. Despite epidemiological heritability estimates
113 of 60-70% for NTDs⁷, few genes are implicated in human NTDs, potentially due to
114 genetic heterogeneity. Additive effects of common SNPs have been proposed, especially
115 in the folate metabolism gene *MTHFR* (C677T, p.Ala222Val), but meta-analysis from 22
116 different association studies suggest only a modest risk (OR 1.23, 95% CI: 1.07–1.42)⁸.
117 Inherited mutations in *VANGLI2*, *TBXT*, *CCL2*, *CELSR1* were identified in cohort
118 studies⁹⁻¹², but represent only a few percent of cases. Prior successes in de novo mutation
119 (DNM) approaches in conditions like autism and congenital heart disease, where
120 mutations are potentially under purifying selection^{13,14}, prompted a trio approach in 43
121 families, identifying recurrent mutations in *SHROOM3*¹⁵, but left unanswered whether
122 larger studies would be better powered.
123

124 **Establishing the Spina Bifida Sequencing Consortium**

125 A critical step in DNM discovery is assessment for an excess burden of damaging
126 mutations in cases vs. controls¹³. With the conservative assumptions of a modest increase
127 in damaging DNMs in cases and estimating perhaps 50–100 total MM genetic risk loci,
128 we calculated that a cohort of 300–500 trios would be required to identify 5–10
129 recurrently mutated genes (see **Supplementary Information** and **Extended Data Fig.**

130 1). In 2015, we thus established the Spina Bifida Sequencing Consortium (SBSC) to
131 aggregate prior CDC (Centers for Disease Control and Prevention, USA)-supported trio
132 recruitment efforts, alongside targeted new recruitment from specialists in more than 12
133 countries, and through social media outreach. Recruitment was limited to diagnosis of
134 MM probands with open neural tissue observed at birth and hydrocephalus requiring
135 shunting, specifying the most severe form of MM compatible with long term survival
136 (**Methods**). Our ethnically diverse cohort was designed specifically to assess risk from
137 DNMs using trio sequencing, matched with 732 control trios from the Simons Simplex
138 Collection¹⁶. After five years of recruitment, we had enrolled 325 trios, performed trio
139 whole exome sequencing (WES) and DNM analysis, but found no recurrently mutated
140 genes, so we extended the recruitment timeline for an additional five years, to double the
141 cohort size.

142 After 10 years of recruitment, we assembled a cohort of 851 MM trios (839 trios
143 and 6 quartets) consisting of exome sequence data of 2,541 individuals. SBSC was
144 populated by 15 different worldwide sites, incorporating both historic CDC-assembled
145 cohorts and an aggregated earlier report of 39 NTD trios (35 trios and 2 quartets)¹⁵.

147 **Excessive damaging DNM burden in MM trios**

148 After a series of strict quality controls and kinship analyses applied to trio exomes, we
149 constructed a high-confidence call set of 2,592 DNMs (1,458 from 777 MM trios, and
150 1,134 from 725 control trios) (**Methods**), and confirmed strong DNM signatures¹⁷
151 (**Extended Data Fig. 2a–2b**). The rates of the total and functionally categorized DNMs
152 (LGD: likely gene disrupting, D-Mis: damaging missense, tolerant missense, and
153 synonymous) were calculated for the jointly covered consensus regions (**Fig. 1a**),
154 wherein total DNM rates lie in a Poisson distribution (**Extended Data Fig. 2c–2d**,
155 **Methods**). The average mutation rates of total DNMs were 1.22×10^{-8} (1.13×10^{-8} – 1.31
156 $\times 10^{-8}$, 95% CI) in MM and 1.18×10^{-8} (1.09×10^{-8} – 1.28×10^{-8} , 95% CI) in controls,
157 which did not differ significantly (**Extended Data Fig. 2e**, Wilcoxon rank-sum test P
158 value: 0.56), and were also comparable to the rates from previous studies (1.08×10^{-8} –
159 1.32×10^{-8})^{18,19}.

160 In contrast, we observed an excessive rate of LGD DNMs (frameshift Indels,
161 stop-gained, and splice donor/acceptor mutations) in MM (1.2×10^{-9}) compared to
162 controls (5.0×10^{-10}) (**Fig. 1b**), with a ratio of the two Poisson rates (or rate ratio)²⁰ of
163 2.10 (P value: 9.0×10^{-6}). Case-control comparison of DNM rate per proband (i.e.
164 theoretical rate: 0.12 in MM vs. 0.05 in controls, see **Methods**), suggested that 7.2%
165 (95% CI: 2.96%–11.36%) of MM probands display LGD DNM implicated in MM risk
166 (**Table 1**). Based upon the excessive burden, approximately 52.43% of LGD DNMs in
167 MM probands was estimated to contribute to MM risk (**Methods**), comparable with rates
168 in other complex diseases such as Tourette (~51.3%) and autism spectrum disorders
169 (~42%)^{13,21}. When LGD DNMs were considered alongside D-Mis DNMs (i.e. LGD + D-
170 Mis; referred to as ‘damaging DNMs’), 28.26% (95% CI: 7.75%–48.76%) were linked to
171 MM risk with excessive burden. Of note, a subset of high confidence D-Mis DNMs
172 (referred to as ‘D-Mis-HC’) based upon pathogenicity prediction, conferred
173 approximately 80% of the total LGD risk burden (rate ratio: 1.86, P value: 2.0×10^{-6}).
174 Paternal and maternal ages, expected to be correlated with DNM occurrence^{22,23}, were not

175 correlated with the excessive DNMs burden (**Extended Data Fig. 3a**). Moreover, there
176 was no enrichment in tolerant and synonymous missense DNMs.

177 In 3,060 genes considered to be highly constrained (i.e. the probability of loss-of-
178 function intolerance: $pLI \geq 0.9$), the burden of D-Mis DNMs appeared even more
179 significant (rate ratio: 2.10, $P = 0.003$) (**Fig. 1c**). Furthermore, we observed a
180 substantially increased burden of D-Mis-HC DNMs (rate ratio: 7.7, $P = 0.002$). This
181 contrasts with the DNM contributions of other complex diseases, where LGDs play
182 outsized roles compared with D-Mis DNMs¹³.

183 To assess whether there is major missed heritability using WES compared with
184 whole genome sequencing (WGS), we recruited an additional 101 trios and 1 quartet, and
185 performed WGS using standard discovery pipelines (**Methods**). We identified non-
186 recurrent de novo SNV/Indels at expected rates of 1.72×10^{-8} (vs. 1.2×10^{-8} – 2.4×10^{-8} in
187 previous publications^{19,24}, see **Extended Data Table 1**), encompassing 9 putative splice-
188 disrupting and 41 in putative enhancer/promoter regions (**Supplementary Data**). Copy
189 number variant (CNV) analysis revealed two nonrecurrent deletions and two duplications
190 ($> 100\text{kb}$), a rate comparable to other complex diseases^{25,26} (**Extended Data Fig. 3b** and
191 **Extended Data Table 2**). De novo inversions or translocations were not observed. In
192 contrast, a high LGD rate (0.13 per proband) in coding region was replicated in WGS,
193 with three overlapping genes observed in the WES cohort (*KDM1A*, *ITPR3*, and
194 *GRHL2*). Overall, WGS-based analysis mirrored the findings from WES and did not
195 identify an additional major class of mutation (see **Supplementary Information**).

196

197 **Functional convergence of DNM genes in MM**

198 Out of 198 damaging DNMs (82 LGD and 116 D-Mis) found in MM trios, Sanger
199 sequencing was conducted in 86% (170 out of 198) where sufficient DNA was available,
200 yielding 96.5% validation rate, which removed six false DNMs. The remaining 192
201 damaging DNMs (79 LGD and 113 D-Mis) occurred in 187 unique genes, with only five
202 genes mutated in two separate trios (referred to as ‘doubleton’; *PAX3*, *IRS1*, *ZSWIM6*,
203 *BRSK2*, and *VWA8*) (**Fig. 2a** and **Supplementary Data**). Notably, only *PAX3* was
204 previously implicated in human NTDs^{15,27}. Among genes identified as singletons, only
205 *TBXT* (splice donor) and *CELSR1* (frameshift) were previously implicated as inherited
206 NTD risk factors^{9,11}. The lack of additional recurrently mutated genes underscores a
207 significant gap in our current understanding of MM genetic risk factors.

208 Spatial transcriptomic analysis of 36 of the damaging DNM genes confirmed
209 expression at mouse embryonic day 10.5 coinciding with neural tube closure (MERFISH,
210 see **Methods**, **Extended Data Fig. 4**). We found that most genes were expressed broadly
211 in the embryo (86%, 31 out of 36), but a minority (14%) showed some cell type specific
212 expression such as *Celsr1* in neural progenitors and *Stab1* in neural crest progenitors
213 (**Extended Data Fig. 5**, **Supplementary Information**).

214 We next studied the protein interactions of MM DNM genes using the STRING
215 database²⁸ (**Fig. 2b**). Among the 187 genes, 107 (57%) including 4 doubletons, 33 LGDs,
216 and 74 D-Mis were highly interconnected, compared to controls (38% interconnected)
217 (**Extended Data Fig. 6**). Bootstrap analysis confirmed a significantly greater degree of
218 network colocalization than genes in the control group (**Fig. 2c**, **Methods**, two-sided
219 Wilcoxon rank-sum test, P value $< 1.0 \times 10^{-16}$). Genes exhibiting a higher node degree (n
220 ≥ 6) were predominantly observed in the MM gene set (Wilcoxon rank-sum test, one-

221 sided) (**Fig. 2d**). Indeed, MM DNM genes were significantly enriched in biological
222 pathways such as morphogenesis of polarized epithelium, neuronal cell adhesion, neural
223 tube closure, and signal transduction (Gene Ontology biological processes, adjusted P
224 values < 0.05) (**Fig. 2e and Extended Data Table 3**), suggesting functional convergence
225 in neural tube closure.

226

227 **DNMs implicate functional modules in neural tube closure**

228 Using the 187 MM DNM genes as seeds, we employed network propagation to construct
229 a comprehensive gene network associated with human MM risk (**Extended Data Fig. 7**,
230 see **Methods**)²⁹, by implicating functionally related genes that might not be directly
231 observable in patients due to, for instance, lethal mutations. The propagated network
232 ‘Meningomyel-ome’ comprised 439 genes, including 257 propagated genes, and
233 exhibited 2,447 interconnected edges. We found an over-representation of 374
234 experimentally proven mouse NTD causal genes³⁰ (**Supplementary Data**) in both seed
235 and propagated genes (11 and 17 of the mouse NTD genes in before- and after
236 propagation, one-tailed hypergeometric P value: 0.0015), corroborating functional
237 relatedness to human MM. In contrast, no such relatedness was found with propagation in
238 genes carrying DNMs in control trios (P value: 0.295).

239 Applying a clustering algorithm³¹ to the ‘Meningomyel-ome’, we identified five
240 subnetworks in which damaging DNMs and propagated genes were closely connected
241 and enriched within predefined signaling pathways (referred to as submodules):
242 RHO/RAC1 GTPase based actin cytoskeleton organization, microtubule-based process,
243 neuronal migration and axon guidance, metabolism of lipids, and histone modification
244 (FDR $< 10^{-5}$, **Fig. 3a**, see **Methods**)^{6,32-38}, suggesting that disrupting these pathways can
245 increase MM risk. Notably, a higher haploinsufficiency of the 51 propagated genes
246 within the submodules (pLI = 0.98 vs. 0.69 of 46 seed genes in median, see **Extended**
247 **Data Fig. 8**) substantiated the utility of network propagation to further implicate
248 potentially lethal MM risk genes.

249 Common among the twelve most strongly associated signaling pathways with
250 FDR below 10^{-8} was actin and microtubules organization processes (**Fig. 3b**). Functional
251 relatedness to other submodules of higher-level processes^{39,40} and essential roles in the
252 neural fold adhesion and closure^{41,42} suggest that RHO/RAC1 GTPase-mediated actin and
253 microtubule organization processes contribute to human MM risk.

254

255 **Functional validation of candidate MM genes**

256 We next performed functional assessment of candidate MM DNM alleles or genes. Seven
257 genes—*TNK2*, *TIAM1*, *PLCE1*, *BRSK2*, *CLIP2*, *VWA8*, and *WHAMM*—were selected by
258 their relevance to the RHOA/RAC1/CDC42-mediated actin and microtubule
259 polymerization, five of which are direct regulators (**Fig. 4a, Methods**). Patient mutations
260 in these genes were all D-Mis DNMs usually in regulatory domains predicted to interfere
261 with protein function, except for LGD mutation in *WHAMM* predicted to truncate the
262 protein. *TNK2* is a CDC42-activated kinase that phosphorylates WASP among other
263 targets. We found that immunoprecipitated *TNK2* p.P186L DNM had approximately
264 60% reduced kinase activity to a WASP pseudo substrate, as benchmarked against
265 wildtype and kinase-dead versions (**Fig. 4b and Extended Data Fig. 9**). *TIAM1* is a Src-
266 activated RAC1-specific guanine nucleotide exchange factor that promotes filamentous

267 actin (F-actin) assembly. We found that wild type TIAM1 but not the TIAM1 p.H1149P
268 DNM co-localized with filamentous actin (**Fig. 4c-d**). While basal Rac1 activation was
269 unperturbed, p.H1149P showed significant reduction in Rac1 activation following co-
270 expression with constitutively activate Src (**Fig. 4e** and **Extended Data Fig. 10**). VWA8
271 is a recurrently mutated mitochondrial matrix-targeting ATPase. We found that the
272 p.R230G proband mutation failed to produce VWA8 protein evidenced on Western blot
273 when transfected in HEK293T cells (**Extended Data Fig. 11**). Assessment of CLIP2,
274 BRSK2 and PLCE1 MM proband mutations did not report robust defective protein
275 function in standard assays (**Extended Data Fig. 12-14**). Interestingly the DNM
276 mutations showing impaired protein function have previously been directly or indirectly
277 linked to NTDs in animal models (see **Supplementary Information**). Thus, half of the
278 six missense mutations showed clear disrupted function, consistent with our predicted
279 rate of DNMs contributing to MM risk (52.43% of LGD, and 28.26% of damaging
280 DNMs).

281 An LGD mutation found in *WHAMM* was selected for *in vivo* functional
282 assessment in a *Xenopus laevis* neural tube closure model. Splice-blocking morpholino
283 (MO) of the orthologous *Whamm* protein (**Methods**) resulted in dose-dependent NTDs
284 (**Fig. 4f-h**). Specifically, injection of 5 ng of MO led to mild NTD, while 10 ng injection
285 resulted in more severe open NTD in both anterior and posterior regions, as evidenced by
286 *pax3* in situ hybridization, and was rescued by expression of wildtype *Whamm*
287 (**Extended Data Fig. 15**). These findings confirm the role of at least one of the DNM
288 genes in MM pathogenesis *in vivo* and underscore potential gene dosage effects
289 contributing to MM risk.

291 **Expanding clinical phenotypes to include MM**

292 We noted that 82 of the MM DNM genes were previously implicated in syndromic or
293 nonsyndromic phenotypes in the Online Mendelian Inheritance in Man (OMIM) database
294 ⁴³, raising the question of whether our MM subjects might also express some of these
295 OMIM phenotypes. By recontacting families, we found that 6% (5 out of 83) of the MM
296 subjects (i.e. with mutations in *ZSWIM6*, *PAX3* in two subjects, *TCF12* and *BICRA*) had
297 clinical features in addition to MM (Acromelic frontonasal dysostosis, Waardenburg,
298 Craniosynostosis and Coffin-Siris syndromes, respectively), that suggest MM as a
299 phenotyping expansion (**Supplementary Table 1**). Some subjects were lost to follow up,
300 leading to 21.6% of the phenotypes that could be excluded due to lack of full clinical
301 information. An additional 2 subjects (2.4%) shared some clinical features with OMIM
302 phenotypes but insufficient to make the clinical diagnoses. For the majority of these 82
303 subjects, the zygosity did not match the OMIM zygosity (i.e. dominant vs. recessive), so
304 it was not surprising that 70% of subjects lacked any OMIM clinical features. We
305 conclude that MM can infrequently present as partially penetrant phenotype in
306 established OMIM disorders, and suggest that specific alleles or environmental factors
307 may determine expressivity.

309 **Discussion**

310 In this study, we present the first large-scale assessment of DNMs contributing to MM
311 risk. Approximately 22% of MM probands had damaging DNMs, of which about 28%
312 were expected to contribute to MM risk. This risk is comparable to other severe pediatric


313 conditions that are likely under strong purifying selection, as the mutations are unlikely to
314 propagate to offspring⁴⁴⁻⁴⁶. In addition to the LGD DNMs found in other severe pediatric
315 conditions, we found strong enrichment of D-Mis DNMs, suggesting that some LGD
316 mutations in these genes may be lethal during embryogenesis. It would be interesting to
317 assess the contribution of D-Mis mutations in other severe pediatric conditions.

318 Although only a subset of the genes identified likely contribute risk, we found that
319 candidate MM genes were more interconnected than expected by chance. This lends
320 support to the existence of a ‘Meningomyel-ome’, characterized by numerous genes that
321 have potential to affect phenotype, interconnected by regulatory or protein-interaction
322 networks, aligning with an omnigenic model⁴⁷. Many of the networks highlight pathways
323 previously implicated from mouse or frog models, including Wnt signaling, planar cell
324 polarity, actin regulation and cell signaling. Notably, there was little overlap of mutated
325 genes in humans with animal NTD models. One difference is that mouse and frog NTD
326 genes are often identified as lethal embryonic phenotypes^{48,49}, whereas our ascertainment
327 was limited to living subjects. Thus, while the genes implicated in laboratory animals vs.
328 human NTDs may be different, we expect the pathways to be highly similar, evident in
329 the Meningomyel-ome. Future work could introduce human DNMs into vertebrate
330 models or human neural tube stem cell models, to bridge this divide.


331 Of the 187 genes with DNMs in MM subjects, 83 were previously implicated in
332 human phenotypes according to OMIM. Only two of these OMIM conditions listed MM
333 as part of the associated spectrum, and in only five subjects was the overlap sufficient for
334 clinical diagnosis of the linked OMIM phenotype. This suggests that MM should be
335 considered as part of the clinical continuum of a variety of OMIM conditions, which may
336 be expressed in an allelic- or zygosity-specific fashion. Surprisingly, only five of the 187
337 genes were recurrently mutated in our cohort, suggesting there could be thousands of
338 genes contributing to MM risk (**Supplementary Information**).

339 Our findings do not resolve the pathogenesis of most MM cases. Rare and de
340 novo copy-number variants⁵⁰, or inherited variants could also contribute to risk⁵¹. It is
341 also possible that regulatory mutations contribute, perhaps modulated by folic acid.
342 Lastly, evidence of gene dosage sensitivity raises the possibility that environmental
343 factors during critical developmental windows might amplify the effects of mutations.

344 **Figures**




345 **Figure 1. Enrichment of damaging DNMs in MM versus control.** **a**, DNMs
 346 categorized by predicted functional impact: LGD (likely gene disrupting), D-Mis
 347 (damaging missense), D-Mis-HC (damaging missense of high confidence, called from a
 348 meta predictor), Tolerant Mis (missense of tolerant functional impact), and Synonymous.
 349 DNM rates per proband in MM (left sides of the triangle with strips) and control (right
 350 sides). Areas represent the ratio of the DNM rates between MM and controls within each
 351 functional category. Hashed: MM; Unhashed: controls. **b–c**, Variant rate (10^{-8}) and
 352 theoretical rate (DNM rate per child) on left and right y-axis, respectively. Statistical
 353 analysis of the ratio of DNM rates between MM (triangles) and controls (circles), denoted
 354 by ratio of the two Poisson rates, or rate ratio (RR), calculated within **(b)** ‘All genes’ ($n =$
 355 19,658) and **(c)** ‘Constrained genes’ ($n = 3,060$; $pLI \geq 0.9$). Theoretical rate was
 356 calculated by normalization of the variant rate with the total size of hg38 coding region
 357 (59,281,518 bp). Observed and theoretical DNM rates are marked in the left and right y-
 358 axis, respectively. P values were calculated by a one-sided rate-ratio test. P values:
 359 *** < 0.001 , ** < 0.01 , * < 0.05 . ns: not significant.
 360
 361



362
363


364 **Figure 2. Functional convergence of genes implicated by damaging DNMs.** **a**,
365 Proportion of singletons (DNM occurred in one trio) and doubletons (DNMs occurred in
366 two independent trios) damaging (LGD or D-Mis) genes in controls (green) and MM
367 (yellow). Six doubleton genes were annotated with variant functional categories (LGD, D-
368 Mis-HC, or D-Mis). **b**, A protein-protein interaction network composed of MM DNM
369 genes. Genes connected by at least one edge are shown; unconnected (orphan) genes are
370 shown in **Extended Data Fig. 3a**. Node color: variant functional categories: LGD (purple),
371 D-Mis (light pink), and D-Mis-HC (dark pink). Doubleton genes: green borders. Edge
372 thickness: confidence score of the protein interaction, defined in the STRING database. **c**,
373 Distribution of the total number of edges in 100,000 networks randomly generated with
374 bootstrapping (selecting gene set size of 108 (i.e. 80% of the 135 control DNM genes) in
375 control (green) and MM (yellow). Higher number of edges denotes denser network
376 interconnection. *P* values calculated by two-sided Wilcoxon rank-sum test. **d**, Number of
377 nodes with *n* (0 to 10) edges in controls (green) and MM (yellow) gene sets. Error bars:
378 first and third quartile. *P* values calculated by a one-sided Wilcoxon rank-sum test. **e**, GO
379 (Gene Ontology) term network visualization for genes overlapping with 187 MM DNM
380 genes with statistical significance (a.k.a., GO enrichment analysis). GO terms of functional
381 relevance connected by an edge via commonly involved genes (small circles). Node sizes:
382 significance of the terms. Degree of connectivity between terms (edges): kappa statistics
383 by ClueGO. *****P* value < 0.0001. ns: not significant.

384
385
386



387
388
389
390
391
392
393
394
395
396
397
398

Figure 3. Functional modules that contribute to MM risk. **a**, Functional submodules clustered from the propagated network, ‘Meningomyel-ome’, with the 187 damaging DNM genes from MM cohort used as seeds. Clustered with a Leiden algorithm with co-expression value from STRING database as attributes, five submodules annotated FDR < 10⁻⁶ by Gene Ontology (GO) Biological Process, KEGG, or Reactome databases shown. **b**, Topmost significantly enriched GO Biological Processes with FDR < 10⁻⁸ shown. FDR value: -log¹⁰ scale. LGD DNMs genes: blue triangle. D-Mis DNMs: blue circles. Propagated genes: small purple circles. Functional terms annotated with FDR < 10⁻⁸ colored with light purple background.



399

400

Figure 4. Functional validation of damaging DNMs related to actin polymerization.

401

a, Damaging DNM genes highlight ‘GTPase involved actin cytoskeleton pathway’

402

mediated by WASP and WAVE, involving three GTPases (CDC42, RAC1, and RHOA)

403

and five mutated genes *TNK2*, *TIAM1*, *WHAMM*, *PLCE1*, and *BRSK2*. Red circle: LGD

404

DNM, Dark yellow circle: D-Mis DNM. **b**, *TNK2* p.P168L patient mutation impaired

405

WASP phosphorylation from immunoprecipitation (IP) kinase assay, compared to WT

406

and kinase dead p.A156T. **c–d**, *TIAM1* p.H1149P patient mutation showed fewer

407

lamellipodia (F-actin) compared to WT, **(c)** imaged with Phalloidin and **(d)** quantified.

408

Kruskal-Wallis followed by a pairwise Wilcoxon test, *P* value adjusted with Bonferroni.

409

Data shown with Hampel filter and images masked to remove other cells. **e**, *TIAM1*

410

p.H1149P patient mutation decreased Rac1 activation with constitutively active (C.A.)

411

Src, observed with Förster resonance energy transfer (FRET). Kruskal-Wallis followed

412

by a pairwise Wilcoxon test, *P* value adjusted with Bonferroni. Data shown with Hampel

413

filter. **f**, Dorsal views of *Xenopus laevis* embryos injected with Whamm morpholino

414

(MO) at Stage 19. Neural tube closure phenotypes observed in a dose-dependent manner

415

with 5 and 10 ng MO. **g**, Neural folds visualized by *pax3* in situ hybridization in the late

416

neural stage. **h**, Quantification of distance between neural folds. Newman-Keuls (two-

417

sided) for control versus multiple conditions after ANOVA. *P* values: **** < 0.0001,

418

*** < 0.001, ** < 0.01, * < 0.05. ns: not significant, LGD: likely-gene disrupting, D-Mis:

419

damaging missense; WT: wild-type.

420 References

- 421
- 422 1 Iskandar, B. J. & Finnell, R. H. Spina bifida. *N Engl J Med* **387**, 444-450 (2022).
423 <https://doi.org/10.1056/NEJMra2116032>
- 424 2 Lee, S. & Gleeson, J. G. Closing in on mechanisms of open neural tube defects.
425 *Trends Neurosci* **43**, 519-532 (2020). <https://doi.org/10.1016/j.tins.2020.04.009>
- 426 3 Prevention of neural tube defects: results of the Medical Research Council
427 vitamin study. MRC Vitamin Study Research Group. *Lancet* **338**, 131-137 (1991).
- 428 4 J, A. *Myelocyste, transposition von gewebskeimen und sympodie*. Vol. Beitr Path
429 Anat 16:1–28, 1894 (1894).
- 430 5 Chiari, H. Uber veränderungen des kleinhirns infolge von hydrocephalie des
431 grosshirns. *Dtsch Med Wochenschr* **17**, 1172–1175 (1891).
- 432 6 Wilde, J. J., Petersen, J. R. & Niswander, L. Genetic, epigenetic, and
433 environmental contributions to neural tube closure. *Annu Rev Genet* **48**, 583-611
434 (2014). <https://doi.org/10.1146/annurev-genet-120213-092208>
- 435 7 Carter, C. O. & Evans, K. Spina bifida and anencephalus in greater London. *J*
436 *Med Genet* **10**, 209-234 (1973). <https://doi.org/10.1136/jmg.10.3.209>
- 437 8 Zhang, T. *et al.* Genetic variants in the folate pathway and the risk of neural tube
438 defects: a meta-analysis of the published literature. *PLoS One* **8**, e59570 (2013).
439 <https://doi.org/10.1371/journal.pone.0059570>
- 440 9 Lei, Y. *et al.* Identification of novel CELSR1 mutations in spina bifida. *PLoS One*
441 **9**, e92207 (2014). <https://doi.org/10.1371/journal.pone.0092207>
- 442 10 Kibar, Z. *et al.* Mutations in VANGL1 associated with neural-tube defects. *N*
443 *Engl J Med* **356**, 1432-1437 (2007). <https://doi.org/10.1056/NEJMoa060651>
- 444 11 Morrison, K. *et al.* Genetic mapping of the human homologue (T) of mouse
445 T(Brachyury) and a search for allele association between human T and spina
446 bifida. *Hum Mol Genet* **5**, 669-674 (1996). <https://doi.org/10.1093/hmg/5.5.669>
- 447 12 Jensen, L. E., Etheredge, A. J., Brown, K. S., Mitchell, L. E. & Whitehead, A. S.
448 Maternal genotype for the monocyte chemoattractant protein 1 A(-2518)G
449 promoter polymorphism is associated with the risk of spina bifida in offspring.
450 *Am J Med Genet A* **140**, 1114-1118 (2006). <https://doi.org/10.1002/ajmg.a.31212>
- 451 13 Iossifov, I. *et al.* The contribution of de novo coding mutations to autism
452 spectrum disorder. *Nature* **515**, 216-221 (2014).
453 <https://doi.org/10.1038/nature13908>
- 454 14 Zaidi, S. *et al.* De novo mutations in histone-modifying genes in congenital heart
455 disease. *Nature* **498**, 220-223 (2013). <https://doi.org/10.1038/nature12141>
- 456 15 Lemay, P. *et al.* Loss-of-function de novo mutations play an important role in
457 severe human neural tube defects. *J Med Genet* **52**, 493-497 (2015).
458 <https://doi.org/10.1136/jmedgenet-2015-103027>
- 459 16 Fischbach, G. D. & Lord, C. The Simons Simplex Collection: a resource for
460 identification of autism genetic risk factors. *Neuron* **68**, 192-195 (2010).
461 <https://doi.org/10.1016/j.neuron.2010.10.006>
- 462 17 Rahbari, R. *et al.* Timing, rates and spectra of human germline mutation. *Nat*
463 *Genet* **48**, 126-133 (2016). <https://doi.org/10.1038/ng.3469>

- 464 18 Kessler, M. D. *et al.* De novo mutations across 1,465 diverse genomes reveal
465 mutational insights and reductions in the Amish founder population. *Proc Natl*
466 *Acad Sci U S A* **117**, 2560-2569 (2020). <https://doi.org/10.1073/pnas.1902766117>
467 19 Besenbacher, S. *et al.* Novel variation and de novo mutation rates in population-
468 wide de novo assembled Danish trios. *Nat Commun* **6**, 5969 (2015).
469 <https://doi.org/10.1038/ncomms6969>
470 20 Frome, E. L. The analysis of rates using Poisson regression models. *Biometrics*
471 **39**, 665-674 (1983).
472 21 Willsey, A. J. *et al.* De novo coding variants are strongly associated with Tourette
473 Disorder. *Neuron* **94**, 486-499 e489 (2017).
474 <https://doi.org/10.1016/j.neuron.2017.04.024>
475 22 Kong, A. *et al.* Rate of de novo mutations and the importance of father's age to
476 disease risk. *Nature* **488**, 471-475 (2012). <https://doi.org/10.1038/nature11396>
477 23 Goldmann, J. M., Veltman, J. A. & Gilissen, C. De novo mutations reflect
478 development and aging of the human germline. *Trends Genet* **35**, 828-839 (2019).
479 <https://doi.org/10.1016/j.tig.2019.08.005>
480 24 Turner, T. N. *et al.* Genomic patterns of de novo mutation in simplex Autism.
481 *Cell* **171**, 710-722 e712 (2017). <https://doi.org/10.1016/j.cell.2017.08.047>
482 25 Martin, J. *et al.* A brief report: de novo copy number variants in children with
483 attention deficit hyperactivity disorder. *Transl Psychiatry* **10**, 135 (2020).
484 <https://doi.org/10.1038/s41398-020-0821-y>
485 26 Sanders, S. J. *et al.* Multiple recurrent de novo CNVs, including duplications of
486 the 7q11.23 Williams syndrome region, are strongly associated with autism.
487 *Neuron* **70**, 863-885 (2011). <https://doi.org/10.1016/j.neuron.2011.05.002>
488 27 Hol, F. A. *et al.* A frameshift mutation in the gene for PAX3 in a girl with spina
489 bifida and mild signs of Waardenburg syndrome. *J Med Genet* **32**, 52-56 (1995).
490 <https://doi.org/10.1136/jmg.32.1.52>
491 28 Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association
492 networks and functional enrichment analyses for any sequenced genome of
493 interest. *Nucleic Acids Res* **51**, D638-D646 (2023).
494 <https://doi.org/10.1093/nar/gkac1000>
495 29 Cowen, L., Ideker, T., Raphael, B. J. & Sharan, R. Network propagation: a
496 universal amplifier of genetic associations. *Nat Rev Genet* **18**, 551-562 (2017).
497 <https://doi.org/10.1038/nrg.2017.38>
498 30 Harris, M. J. & Juriloff, D. M. An update to the list of mouse mutants with neural
499 tube closure defects and advances toward a complete genetic perspective of neural
500 tube closure. *Birth Defects Res A Clin Mol Teratol* **88**, 653-669 (2010).
501 <https://doi.org/10.1002/bdra.20676>
502 31 Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden:
503 guaranteeing well-connected communities. *Sci Rep* **9**, 5233 (2019).
504 <https://doi.org/10.1038/s41598-019-41695-z>
505 32 Rolo, A., Escuin, S., Greene, N. D. E. & Copp, A. J. Rho GTPases in mammalian
506 spinal neural tube closure. *Small GTPases* **9**, 283-289 (2018).
507 <https://doi.org/10.1080/21541248.2016.1235388>

- 508 33 Wallingford, J. B., Niswander, L. A., Shaw, G. M. & Finnell, R. H. The
509 continuing challenge of understanding, preventing, and treating neural tube
510 defects. *Science* **339**, 1222002 (2013). <https://doi.org/10.1126/science.1222002>
511 34 Niederkofler, V., Salie, R., Sigrist, M. & Arber, S. Repulsive guidance molecule
512 (RGM) gene function is required for neural tube closure but not retinal
513 topography in the mouse visual system. *J Neurosci* **24**, 808-818 (2004).
514 <https://doi.org/10.1523/JNEUROSCI.4610-03.2004>
515 35 Kee, N., Wilson, N., Key, B. & Cooper, H. M. Netrin-1 is required for efficient
516 neural tube closure. *Dev Neurobiol* **73**, 176-187 (2013).
517 <https://doi.org/10.1002/dneu.22051>
518 36 Greene, N. D., Stanier, P. & Moore, G. E. The emerging role of epigenetic
519 mechanisms in the etiology of neural tube defects. *Epigenetics* **6**, 875-883 (2011).
520 <https://doi.org/10.4161/epi.6.7.16400>
521 37 Akimova, D. *et al.* Metabolite profiling of whole murine embryos reveals
522 metabolic perturbations associated with maternal valproate-induced neural tube
523 closure defects. *Birth Defects Res* **109**, 106-119 (2017).
524 <https://doi.org/10.1002/bdra.23583>
525 38 Copp, A. J., Stanier, P. & Greene, N. D. Neural tube defects: recent advances,
526 unsolved questions, and controversies. *Lancet Neurol* **12**, 799-810 (2013).
527 [https://doi.org/10.1016/S1474-4422\(13\)70110-8](https://doi.org/10.1016/S1474-4422(13)70110-8)
528 39 Schaar, B. T. & McConnell, S. K. Cytoskeletal coordination during neuronal
529 migration. *Proc Natl Acad Sci U S A* **102**, 13652-13657 (2005).
530 <https://doi.org/10.1073/pnas.0506008102>
531 40 Dent, E. W., Gupton, S. L. & Gertler, F. B. The growth cone cytoskeleton in axon
532 outgrowth and guidance. *Cold Spring Harb Perspect Biol* **3** (2011).
533 <https://doi.org/10.1101/cshperspect.a001800>
534 41 Geelen, J. A. & Langman, J. Closure of the neural tube in the cephalic region of
535 the mouse embryo. *Anat Rec* **189**, 625-640 (1977).
536 <https://doi.org/10.1002/ar.1091890407>
537 42 Rolo, A. *et al.* Regulation of cell protrusions by small GTPases during fusion of
538 the neural folds. *Elife* **5**, e13273 (2016). <https://doi.org/10.7554/eLife.13273>
539 43 Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A.
540 Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes
541 and genetic disorders. *Nucleic Acids Res* **33**, D514-517 (2005).
542 <https://doi.org/10.1093/nar/gki033>
543 44 Jin, S. C. *et al.* Contribution of rare inherited and de novo variants in 2,871
544 congenital heart disease probands. *Nat Genet* **49**, 1593-1601 (2017).
545 <https://doi.org/10.1038/ng.3970>
546 45 Halvorsen, M. *et al.* De novo mutations in childhood cases of sudden unexplained
547 death that disrupt intracellular Ca(2+) regulation. *Proc Natl Acad Sci U S A* **118**
548 (2021). <https://doi.org/10.1073/pnas.2115140118>
549 46 Li, W. *et al.* De novo mutations contributes approximately 7% of pathogenicity in
550 inherited eye diseases. *Invest Ophthalmol Vis Sci* **64**, 5 (2023).
551 <https://doi.org/10.1167/iovs.64.2.5>

- 552 47 Boyle, E. A., Li, Y. I. & Pritchard, J. K. An expanded view of complex traits:
553 from polygenic to omnigenic. *Cell* **169**, 1177-1186 (2017).
554 <https://doi.org/10.1016/j.cell.2017.05.038>
- 555 48 Lemos, M. C. *et al.* Genetic background influences embryonic lethality and the
556 occurrence of neural tube defects in Men1 null mice: relevance to genetic
557 modifiers. *J Endocrinol* **203**, 133-142 (2009). [https://doi.org/10.1677/JOE-09-](https://doi.org/10.1677/JOE-09-0124)
558 [0124](https://doi.org/10.1677/JOE-09-0124)
- 559 49 Momb, J. *et al.* Deletion of Mthfd11 causes embryonic lethality and neural tube
560 and craniofacial defects in mice. *Proc Natl Acad Sci U S A* **110**, 549-554 (2013).
561 <https://doi.org/10.1073/pnas.1211199110>
- 562 50 Bassuk, A. G. *et al.* Copy number variation analysis implicates the cell polarity
563 gene glypican 5 as a human spina bifida candidate gene. *Hum Mol Genet* **22**,
564 1097-1111 (2013). <https://doi.org/10.1093/hmg/dd515>
- 565 51 Wolujewicz, P. *et al.* Genome-wide investigation identifies a rare copy-number
566 variant burden associated with human spina bifida. *Genet Med* **23**, 1211-1218
567 (2021). <https://doi.org/10.1038/s41436-021-01126-9>
568

569 **Tables**

Variant type	Theoretical rate per child (±95% CI)		% of cases with DNM mediating risk (±95% CI)	% of DNM carrying MM risk (±95% CI)
	MM (n=772)	Control (n=724)		
Likely Gene Disrupting (LGD)	0.12 (0.09-0.14)	0.05 (0.03-0.08)	7.16% (2.96%-11.36%)	52.43% (21.67%-83.18%)
Damaging HC	0.18 (0.14-0.21)	0.09 (0.07-0.12)	9.60% (4.45%-14.75%)	46.15% (21.38-70.92)
Damaging	0.29 (0.24-0.33)	0.21 (0.17-0.25)	9.62% (2.64%-16.59%)	28.26% (7.75-48.76)

570

571 **Table 1. Contribution of DNMs to MM risk**

572 The DNM theoretical rate (i.e., DNM rate per child) of MM ($n = 772$) and control ($n =$
573 724) trios are shown with the 95% confidence interval (CI) of the rate using a one-sample
574 t-test. The % of cases with DNM mediating risk were calculated by the difference
575 between the theoretical rate of the MM and the control with 95% CI using a two-sample
576 t-test (two-sided). The % of cases with DNM mediating risk was estimated by dividing
577 the difference of theoretical rate between MM and control, by the theoretical rate of MM
578 trios, with the 95% CI using two-sample t-test. The theoretical rates were calculated
579 based on consensus regions for proper comparison of DNM rates. Damaging DNM
580 includes LGD (Likely Gene Disrupting) and D-Mis DNM. Damaging-HC (high
581 confidence) includes LGD and D-Mis-HC (high confidence).

582 **Methods**

583

584 **Establishment of Spina Bifida Sequencing Consortium (SBSC) cohort**

585 *Inclusion criteria*

586 Strict inclusion criteria were set for subject enrollment into the Spina Bifida Sequencing
587 Consortium (SBSC). Participants must be affected by lumbosacral meningomyelocele
588 (MM) with Arnold-Chiari malformation and hydrocephalus requiring surgical
589 intervention such as ventriculoperitoneal shunt or endoscopic third ventriculostomy. We
590 excluded subjects with closed neural tube defects, not requiring surgery at birth, with
591 meningocele, or without hydrocephalus or not requiring surgery at birth. Enrollment
592 required that both biological parents were available for sampling. In the case of fetal
593 surgery to correct MM, which reduces the incidence of hydrocephalus, the requirement
594 for inclusion of hydrocephalus at the time of enrollment was lifted. Subjects with known
595 syndromes that would explain their conditions were excluded. Any families that did not
596 meet the strict inclusion criteria were excluded.

597

598 *Recruitment*

599 The SBSC used several concurrent recruitment approaches: 1] Identify recruitable MM
600 trios from local, national, and international hospitals. 2] Social media outreach through
601 the Spina Bifida Association (SBA) Twitter, Facebook and Instagram accounts directly to
602 families. 3] Recruit from spina bifida multidisciplinary clinics around the world with high
603 MM caseloads. 4] Leverage historic Center for Disease Control-supported neural tube
604 defect (NTD) cohorts. 5] Share sequencing data that have been already generated from
605 trios with members of the SBSC and publicly with the NIH supported dbGaP. 6] Subjects
606 and/or their families also contacted the SBSC independently through our postings and
607 advertisements on social media. The countries where the participants were recruited
608 include the United States, Mexico, Brazil, Italy, Georgia, Egypt, Canada, Venezuela,
609 Pakistan, Guatemala, and Nigeria. All subjects or their guardians provided written
610 informed consent approved by the UCSD Institutional Review Board S99075 protocol
611 140028, expiration date Aug 1, 2024. Recruitment processes were conducted in
612 accordance with the approval by review boards of the University of California San Diego,
613 operating under Federal-wide Assurance number, FWA00004495. The above rulings
614 cover all aspects of our study, not just recruitment and consent.

615

616 *Identifiers*

617 The subject IDs used in this study cannot reveal the identity of the study subjects. These
618 IDs are not know to anyone outside the research group.

619

620 *Study questionnaire*

621 All families prospectively recruited completed a standardized SBSC Questionnaire,
622 which confirmed inclusion criteria, documented past medical history and current status
623 by adopting prior questionnaire fields⁵², along with place and date of birth of affected and
624 parents to control DNM rate for parental age at the time of conception.

625

626 *Subject sample and data handling*

627 DNA was extracted from blood or saliva by standard salt extraction protocols using
628 Qiagen (Germantown, MD) or Autogen (Holliston, MA) proto\ prior CDC-funded
629 recruitment efforts where recontact was not possible, and thus they were considered ‘lost
630 to follow-up’ for sample re-collection. There were 37 families that had prior trio WES¹⁵
631 where data was incorporated into the cohort using the standardized bioinformatics
632 pipeline.

633

634 **Sequence data generation**

635 In total, 2541 samples from 851 MM trios (839 trios and 6 quartets) were eligible for
636 whole exome sequencing with six target capture kits (Roche Exome V2, Agilent xGen
637 Exome V1, Agilent SureSelect v4, Agilent SureSelect V4, IDT xGen Exome V2, and
638 Twist human comprehensive exome), each trio sequenced by using the same capture kit.
639 Samples with low concentration of DNA, gender discordant, or contamination yielded 45
640 samples to be failed quality control, resulting in 794 trios and 6 quartets. For control trios,
641 we obtained 732 healthy trios from the SAFARI cohort¹⁶, 2202 WES data captured with
642 NimbleGen EZ v2.

643

644 **Data preprocessing and quality control**

645 Raw reads were aligned to reference genome (GRCh38) using bwa mem (0.7.17),
646 preprocessed with PICARD (2.20.7) AddOrReplaceReadGroups and MarkDuplicates.
647 Germline variants were collected with GATK (v4.11.0) HaplotypeCaller in the reference
648 confidence model (-ERC GVCF) to be combined via CombineGVCF, generating a joint
649 vcf for all MM and control trios, followed by GenotypeGVCF (v4.11.0) to be jointly
650 genotyped. Multiallelic variants were splited (bcftools norm -m -any), Indels were
651 realigned, and base quality recalibration was done with GATK (v.4.0.11) with known
652 Indel and population frequency information (dbSNP (146) and
653 Mills_and_1000G_gold_standard.indels.hg38.vcf.gz from GATK resource bundle).
654 Variant quality was recalibrated by GATK VQSR with HapMap
655 (hapmap_3.3.hg38.vcf.gz), omni (1000G_omni2.5.hg38.vcf.gz), 1000G
656 (1000G_phase1.snps.high_confidence.hg38.vcf.gz),
657 (Mills_and_1000G_gold_standard.indels.hg38.vcf.gz), and axiom
658 (Axiom_Exome_Plus.genotypes.all_populations.poly.hg38.vcf.gz).
659 To confirm the kinship integrity within trios, we used TRUFFLE⁵³ (v1.38), removing 29
660 and 7 trios from MM and control cohort, respectively. IBD1 values were extracted from
661 the vcf, by only using variants with allele frequencies higher than 0.05 (--maf 0.05) to
662 only use confident calls. The IBD1 for all possible sample pairs were examined and if a
663 parent-child IBD1 value is smaller than 0.75. Also, samples having more relations (IBD1
664 ≥ 0.75) with one outside of their family were removed, possibly owing to low data
665 quality or contamination.

666

667 **De novo variant calling**

668 De novo SNVs and Indels were collected following GATK genotype refinement steps.
669 The genotypes of 777 MM and 725 control trios were gathered, and posterior
670 probabilities of the variants were calculated with CalculateGenotypePosteriors (v4.2.6.1).
671 We only selected de novo variants having genotype qualities (GQ) ≥ 20 , Mapping quality
672 (MQ) ≥ 30 , and PASS in VQSR. Candidate DNMs that were found to have sequencing

673 depth (DP) ≥ 12 in all three family members were kept to secure high-confident calls. To
674 remove candidates that deviate from theoretical heterozygous states (AF=0.5), a two-
675 sided binomial test was conducted to all positions by applying read depths and number of
676 alternative alleles, removing sites with P value > 0.01 . Genotypes of both parents were
677 examined and kept if genotyped as reference homozygous (GT=0/0). To enhance the
678 robustness of a high-confident set of DNMs, a series of post-filters were applied, by
679 examining regional information and raw allele counts. First, clustered DNMs were
680 filtered out when two or more DNMs of one proband were observed within 10 bp.
681 Second, DNMs that were found to exist in the same genotypes in parents either in MM or
682 control cohorts were also removed. For de novo SNVs, each DNM position was
683 examined by collecting raw reads with base quality (> 13) and mapping quality (> 0)
684 criteria for each trio (bcftools mpileup v1.9). Then, to remove artifacts derived from
685 miscellaneous alignment, a position was filtered out when a same alternative allele was
686 observed in either of the parents. Two-sided binomial test was once more applied for
687 SNVs with raw read counts, with a strict cutoff 0.05. All Indels were manually inspected
688 with IGV (Integrative Genomics Viewer) by three experienced experts. The schematic
689 overview of the DNM detection pipeline is shown in **Extended Data Fig. 16a**. VEP
690 (v106) was used to annotate de novo variants with 1000 genomes (phase 3), COSMIC
691 (92), ClinVar (202109), ESP (V2-SSA136), HGMD-PUBLIC (20204), dbSNP (154),
692 GENCODE (Human Release 40), gnomAD (r2.1.1), PolyPhen (2.2.2) and SIFT (5.2.2).
693 Mutational signatures were collected by Mutalisk⁵⁴ using linear regression.

694

695 **DNM statistical confirmation**

696 *Consensus region for DNM rate calculation*

697 To compare DNM rates and burden among sequencing data generated with different
698 platforms (e.g., exome capture libraries), genomic regions that are commonly covered
699 with sufficient coverage (that is, consensus region) were extracted. For each individual
700 genome coverage was calculated using bedtools⁵⁵ (v 2.30.0) genomecov. Then, the
701 coverage bedgraphs were merged into each trio using bedtools unionbedg, and only the
702 regions with read depth ≥ 12 in all three family members were kept. Each family
703 bedgraph was merged with bedgraphs of other families within each batch, to confirm if at
704 least 70% of families covered that region. Finally, the batch bedgraphs were merged into
705 a final consensus region, reaching 36,553,428 bp.

706

707 *DNM rates examined with Poisson distribution*

708 DNMs located in the consensus region were collected, to confirm if the number of DNM
709 per proband follows an expected Poisson distribution. Briefly, we assumed a cutoff of
710 DNM count per proband from 1 to 20, generating DNM sets based on the cutoffs. Then,
711 an expected Poisson distribution was generated per cutoff, with lambda as an average
712 count of DNMs per proband (R dpoi). An observed distribution of DNMs per proband
713 was calculated to be compared to the expected distribution, with Chi-Square goodness-of-
714 fit test (R chisq.test). A cutoff of 7 DNMs per proband was set (**Extended Data Fig. 2c–**
715 **2d**), removing five and one trios from MM and controls, respectively. The six samples
716 with DNM counts larger than 7 were found to have DNMs ranging from 8 to 484,
717 possibly owing to low data quality.

718

719 **DNM burden analysis**

720 DNM rates were calculated based on the number of DNMs observed in the consensus
721 region, to properly compare the rates. We utilized a rate ratio test given that the number
722 of DNMs per proband followed Poisson distribution. The DNMs were categorized into
723 likely gene disrupting (LGD) including frameshift Indels, stop gained, and splice
724 donor/acceptor mutations. Among the missense variants, if annotated as ‘probably
725 damaging’ or ‘likely damaging’ in PolyPhen or ‘deleterious’ in SIFT, when CADD
726 prediction score (>20) supports either at the same time, we annotated DNMs as damaging
727 missense (D-Mis). If a DNM was annotated as D (deleterious) by a highly strict meta
728 predictor MetaSVM⁵⁶, we prioritized them as D-Mis-HC. We could replicate the highly
729 consensus D-Mis mutations and their burden with two other independent missense
730 variant annotation predictors, MetaLR⁵⁶ and REVEL⁵⁷ (**Supplementary Information**
731 **and Extended Data Fig. 16b**). MetaSVM, MetaLR, and REVEL was annotated based
732 on dbNSFP (4.1a). Missense mutations that were not annotated as D-Mis were
733 categorized as ‘Tolerant missense’. Constrained genes were collected with pLI \geq 0.9.
734 DNM rate was calculated within the consensus region (36,553,428 bp) in the mutation
735 categories, with 95% confidence intervals calculated (one sample t test). Two-sided
736 Wilcoxon rank-sum test was utilized to confirm the difference of the total DNM rates
737 between MM ($n = 772$) and controls ($n = 724$). Rate ratio test (one-sided) was used to
738 compare two Poisson distributed rates from each cohort. Theoretical DNM rates were
739 estimated based on the total size of the coding region in hg38 (59,281,518 bp). The
740 percentage of the subjects with DNM mediating risk could be calculated by the difference
741 between the theoretical rates (DNM rate per exome) of the MM and control (95% CI
742 calculated with Wilcoxon rank-sum test, two-sided). The percentage of DNM carrying
743 the MM risk was estimated by dividing the difference of theoretical rate by the theoretical
744 rate of MM trios.

745

746 **Whole genome analysis**

747 We additionally recruited 101 trios and 1 quartet with MM and generated whole genome
748 sequencing (WGS) data with Illumina HiSeq2500 and NovaSeq. The reads were
749 preprocessed and aligned with the same pipeline of WES data. Same quality controls with
750 WES data were applied, removing 4 trios that failed kinship integrity and contamination
751 analyses. Small SNVs and Indels were collected with the same variant calling and
752 filtering of WES analysis. We applied a binomial test to confirm if a DNM was derived
753 from a heterozygous state as in WES, with applied stronger P value cutoff 0.05 compared
754 to WES, as WGS data has much stable coverage with reduced capture bias and allelic
755 imbalance. Additional populational allele frequency information (gnomAD genome
756 v3.1.2) was added and SpliceAI (v1.3.1)⁵⁸ was utilized (score > 0.5) to predict splice
757 disrupting variants. We annotated noncoding variants with GREEN-VARAN⁵⁹ (GREEN-
758 DB schema 2.5) to annotate DNMs in noncoding regions. For copy number variant
759 analysis (CNV), CNVpytor (1.3.1)⁶⁰ was utilized with a window size of 100 kbp, and
760 manually curated by confirming the read depths of all father and mother. To
761 comprehensively detect structural variants (SVs), we utilized Manta⁶¹ (1.6.0), Delly⁶²
762 (v0.8.1), and smoove⁶³ (0.2.6) and merged the SV calls from the three callers with
763 Survivor (1.0.7, parameter: dist=50000, callers=0, type=0, strands=0, estimate=0,

764 size=50000) to confirm if the detected SVs only present in probands.

765

766 **Multiplexed Error Robust In-Situ Hybridization (MERFISH)**

767 MERFISH was performed as described previously at the UCSD Epigenomics Core⁶⁴.

768 Briefly, mouse embryos at day 10.5 were fixed in paraformaldehyde and cryopreserved in
769 30% sucrose, embedded in Optimal cutting temperature (OCT) and sectioned into 12 μm
770 sections in cryostat. These tissue sections then underwent fluorescent in situ hybridization
771 with a panel of oligonucleotide probes specific for 36 of the genes identified from the
772 current human DNM cohort along with 107 marker genes, chosen upon previously
773 published single cell literatures to classify cell types into 7 cell types (neuron, neural
774 progenitor, neural crest, pre-epithelial to mesenchymal transition neural crest progenitor
775 (Pre-EMT-NCP), dorsal root ganglia, blood and mesoderm⁶⁵⁻⁶⁷. During downstream
776 analysis marker genes were filtered to only include 66 the most efficient markers specific
777 for each cell type (see **Supplementary Data** for a full list of utilized marker genes).

778 Probes were designed and manufactured with standard pipeline by Vizgen

779 (<https://vizgen.com/gene-panel/>). Tissue sections were prepared and processed using

780 Vizgen sample preparation protocol (Document Number 91600002 Rev A), then samples

781 placed in the Merscope for imaging and decoding (Document Number 91600001, Rev

782 G). Raw data was analyzed using Scanpy (1.9.1)⁶⁸. Cells were preprocessed and filtered

783 using the following criteria: cells with volume less than 100 μm^3 , cells with volume

784 larger than 3x median volume of all cells, fewer than 4 genes detected, fewer than 10

785 transcripts detected, total RNA counts lower than the 2% quantile or higher than 98%

786 quantile. Preprocessed cells were clustered based on gene expression using the Leiden

787 algorithm (leidenalg 0.10.2), annotated using scType⁷³ (v1.0) based upon marker genes as

788 the reference set (see **Supplementary Information**). Clusters were annotated to the cell

789 type with the highest overall score from scType, accounting for expression of all marker

790 genes per cell type in a focal cluster, compared to the expression in other clusters.

791 Clusters with prediction score less than 0 or low confidence scores (score less than 10%

792 of the number of cells in each cluster) were classified as indeterminate as they could not

793 be classified in any of the 7 cell types. Expression of each of the 36 candidate genes was

794 then analyzed in each cell from raw data, and percentage of total average expression per

795 cell type calculated in **Extended Data Fig. 5**.

796

797 **Network analysis (co-localization and degree)**

798 Relationship between damaging DNMs in MM vs. control cohorts and the human

799 genome network were calculated using STRING (v11.5) for gene interactions. We

800 calculated the connectedness from the STRING database of damaging DNMs from MM

801 ($n = 187$) and control ($n = 135$) among 19,699 annotated genes, randomly resampled with

802 a size of 80% of the gene set from control ($n = 108$), of 100,000 iterations. Number of

803 edges per iteration were compared with a Wilcoxon rank-sum test (two-sided). Edges per

804 nodes were compared between the cohorts (Wilcoxon rank-sum test, one-sided).

805

806 **Pathway enrichment analysis**

807 To estimate if the MM or control DNM gene sets were functionally enriched in known

808 biological pathways, gene ontology (GO) biological process, reactome, and KEGG

809 pathways, we conducted a gene enrichment analysis with ClueGO (v2.5.10) in Cytoscape

810 (3.10.1), with parameters set as Evidence All_without_IEA (Inferred from Electronic
811 annotation), GO tree interval ranging from 3 to 8, and 5 minimum number of genes, 4%
812 of genes for GO term selection, and 0.4 kappa score. We used adjusted P value with
813 Bonferroni step-down with significance criterion 0.05. Detailed information of the GO
814 enrichment test can be found in **Extended Data Table 3**. No significant term was
815 observed with control gene sets.

816

817 **Sanger confirmation**

818 Out of 198 damaging DNMs, 86% (171 out of 198) where trio DNA samples were
819 available for the Sanger sequencing confirmation, with sufficient DNA. For a subset of
820 detected damaging DNMs, primer sets were generated via Primer3 and ordered from
821 IDT. The primer lengths were configured to span a range of 18 bp to 23 bp, targeting an
822 ideal size of 20 bp. The GC content was set to a minimum of 30% and a maximum of
823 70%, and the annealing temperature was established to range between 57°C and 62°C,
824 with an optimal temperature of 59°C. PCR was performed using the QIAGEN Taq DNA
825 Polymerase kit and primer concentrations of 500 nM. Four reactions were performed per
826 DNM, amplifying DNA from the father, mother, affected child, and an unrelated healthy
827 individual. PCR products were confirmed by agarose gel electrophoresis, purified by
828 incubation with Exonuclease I/Shrimp Alkaline Phosphatase (1:2), diluted in ddH₂O, and
829 shipped to Genewiz/Azenta for Sanger sequencing. Trace files were analyzed in
830 SnapGene Viewer and compared against the UCSC Genome Browser to confirm that the
831 affected child was heterozygous for the detected mutation and the father, mother, and
832 control were homozygous for the reference base at the same locus.

833

834 **Network propagation and submodule identification**

835 A propagated network was constructed with NetColoc (0.1.7)⁶⁹. PCNet⁷⁰ was utilized for
836 the background human gene interaction network, which contains 18,820 nodes and
837 2,693,109 edges. Among 187 MM genes, two genes (SLCO1B3-SLC01B7 and H3-4)
838 couldn't be included as seeds because they couldn't be found in the PCNet. As
839 implemented in NetColoc, w prime and w double prime value was calculated for each
840 gene to generate z scores for proximity. We used the z score threshold 3 as default. The
841 entire list of the genes in the propagated network can be found in **Supplementary Data**.
842 Known mouse NTD genes ($n = 374$) were based on previous literatures, where 205 genes
843 were organized back in 2010³⁰ and the others were added from then (see **Supplementary**
844 **Data** for the gene list). To examine the propagated network, we conducted a
845 hypergeometric test, utilizing 18,820 as the total number of genes as in PCNet ($M =$
846 18,820), number of known NTD genes ($n = 374$), the number of nodes in the propagated
847 network ($N = 439$), and the number of overlapping genes with propagated network and
848 MM genes ($k = 17$).

849

$$Pr(X = k) = f(k; M, n, N)$$

850 Then, to identify small functional modules from the expanded network, the propagated
851 network was clustered with a Leiden algorithm with 0.5 resolution, 0.01 beta with 45
852 iterations. To use co-expression value as attributes, we again transferred the propagated
853 network to STRING database (v12) with Homo Sapiens full STRING network, popping
854 out 114 nodes without edges to the network, meaning discrepant sources of protein
855 network. In total, 15 small clusters were generated with more than five nodes. Five could

856 be significantly enriched by functional biological terms ($FDR < 10^{-5}$) by the GO
857 biological process, KEGG pathway without disease related terms, and Reactome, which
858 had more than 30% of the nodes derived from damaging DNMs (**Supplementary Data**).
859 Two clusters annotated as ‘GTPase involved actin cytoskeleton’ and ‘Microtubule-based
860 process’ were enriched with functional terms with most significant P values ($FDR < 10^{-8}$),
861 with 8 and 4 terms respectively. The pLI of the genes in the five functional modules
862 can be found in **Supplementary Data**.

863

864 **Cloning**

865 Patient DNMs were mutagenized into wildtype (WT) cDNA using Gibson Assembly
866 cloning. These mutations include p.R231G (R230G in mouse) in *Vwa8b* (mouse),
867 p.E521Q and p.E623Q in *PLCE1* (human), p.P168L in *TNK2*, p.H1149P *TIAM1*,
868 p.R620H in *BRSK2* (human) and p.R349C in *CLIP2* (rat). For each of the plasmids,
869 overlapping (40 bp) forward and reverse primers with 20 bp 5' overhangs were designed
870 complementary to the mutation site, with a single nucleobase difference corresponding to
871 the mutation of interest (**Supplementary Data**). 15 ng plasmid DNA was amplified using
872 the NEB Phusion High-Fidelity 2X Master Mix [NEB #M0531] for 25 cycles, after
873 which the reaction was subjected to 1 hour at 50°C with NEBuilder HiFi DNA Assembly
874 2X Master Mix [NEB #E2621], and the reaction mixture was treated with *DpnI* [NEB
875 #R0176] digestion for 37°C for 30 minutes. 2 μ L of the reaction mixture was then
876 transformed into NEB DH5-alpha Competent *E. coli* [NEB #C2987], with successful
877 mutation verified using Primordium whole plasmid sequencing.

878

879 **Protein analysis**

880 ***TNK2***

881 *Cell transfection, lysis, and Western blotting*

882 Human embryonic kidney (HEK)293T cells (from American Type Culture Collection)
883 were maintained in DMEM (Corning) supplemented with 10% fetal bovine serum
884 (Sigma) and 1X penicillin and streptomycin. The cells were transfected according to the
885 protocol supplied with TransIT reagent (Mirus) using 7.5 μ g of DNA. After 48 hours, the
886 cells were harvested, washed with phosphate-buffered saline, and lysed in a buffer
887 containing 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 5
888 μ g/ml leupeptin, 5 μ g/ml aprotinin, 1mM PMSF, and 200 μ M Na₃VO₄. Cell lysis
889 proceeded for 30 minutes at 4°C with rocking. The cell suspensions were centrifuged at
890 15,000 rpm for 10 minutes, and protein concentrations of the soluble lysates were
891 measured using a colorimetric Bradford assay. The lysates (100 μ g) were analyzed by
892 SDS-PAGE and Western blotting using the following antibodies: phospho-Ack1/Tnk2
893 (Millipore Sigma 09-142), Flag (Sigma-Aldrich A8592), and gamma-tubulin (Sigma-
894 Aldrich T6557).

895

896 *Immunoprecipitation (IP) Kinase assay*

897 IP-kinase assays were performed essentially as described with the following
898 modifications: HEK293T lysates (1 mg) were incubated with 40 μ L of anti-Flag M2
899 affinity resin (Sigma) on a rotator at 4°C overnight, then washed three times with Tris-
900 buffered saline (TBS). The IPs were divided into three portions. One portion of each
901 sample was mixed with a gel-loading buffer, boiled for 3 minutes, and analyzed by 7.5%

902 SDS/PAGE with anti-Flag Western blotting. The remaining two samples were used for
903 duplicate activity measurements using the phosphocellulose paper-binding assay. The
904 reactions contained 20 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 0.25 mM ATP, 1 mM
905 WASP peptide (KVIYDFIEKKG) and 20–50 cpm/pmol of [γ -³²P] ATP. Reactions were
906 carried out at 30 °C for 15 min. Incorporation of ³²P into peptide was measured by
907 scintillation counting.

908

909 ***TIAM1***

910 *DNA Reagents*

911 The following constructs were previously described: pCMV-EGFP⁷¹, pCMV-Flag-Tiam1
912 (WT-Tiam1)⁷², pRaichu-RaichuEV-Rac1 (2248X)⁷³, pcDNA3.1 vector⁷⁴. mRuby3 was
913 obtained from Addgene (127808).

914

915 *Cell culture and transfections*

916 Cos-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Corning 10-
917 013-CV) supplemented with 100 U/ml penicillin/streptomycin (Invitrogen 15140122) and
918 10% heat inactivated fetal bovine serum (Atlanta Biologicals S11150H) on cell culture-
919 treated plastic (VWR 10062-880) maintained at 5% CO₂, 37°C. Cells were passaged with
920 trypsin (Invitrogen 25200072) once per week. For experiments, 24 hrs prior to transfection
921 cells were plated on either nitric acid washed glass cover slips (Bellco Glass 1943-10012A)
922 or glass bottom plates (Cellvis P241.5HN) coated with 20 ug/ml Poly-D-Lysine (Corning
923 354210). Cells were transfected using Jetprime reagent (Polyplus 101000046) according
924 to the manufacturer recommendations. Twenty-four hours after transfections cells were
925 changed to serum-free DMEM. For live cell experiments, phenol-red free DMEM (Corning
926 17-205-CV) was used. Experiments were conducted 48 hours after transfection.

927

928 *Immunocytochemistry, microscopy, and analysis*

929 Cells were fixed with 4% Paraformaldehyde (Fisher Scientific AC169650010), 4%
930 Sucrose (Sigma S0389) in phosphate buffered saline (PBS). To confirm construct
931 expression, following fixation all cells were immunostained overnight at 4°C with anti-
932 Flag (Cell Signaling 14793S) primary antibody diluted in 0.3% Triton X-100, 5% goat
933 serum in PBS. After, cells were incubated with Cy5 anti-Rabbit secondary antibody
934 (Jackson ImmunoResearch 111-175-003) for 2 hrs at room temperature. For filamentous
935 actin experiments, cells were also incubated with Texas Red-Phalloidin (Invitrogen
936 T7471) during this time. Post-fixation and staining, cells grown in glass coverslips were
937 mounted using the aqueous mounting solution FluorSave (EMD Millipore 345789).

938

939 *Imaging*

940 Filamentous actin was labeled with Texas Red phalloidin, then imaged using a Zeiss
941 AxioObserver.Z1 microscope with a 20x objective. Rac1 activation was measure in cells
942 transfected with the RaichuEV-Rac1 probe, imaged on a Zeiss LSM 880 confocal
943 microscope at 20x. Live imaging experiments were conducted at 37°C/5% CO₂. Single
944 plane images were acquired with Förster resonance energy transfer (FRET) (excitation 458
945 nm, emission 522–569 nm), CFP (Donor) (excitation 458 nm, emission 463–507 nm), and
946 YFP (Acceptor) (excitation 514 nm, emission 522–569 nm), presented as normalized
947 FRET/Donor values using ImageJ (NIH). Only cells expressing constructs were selected

948 for analysis. GFP or mRuby3 fill visualized cell morphology via ROI cell trace, measured
949 for mean intensity, corrected for background, and normalized to respective controls.
950 Experiments were conducted with experimenters blinded to conditions. Representative
951 images were masked using ImageJ (NIH).

952

953 ***VWA8***

954 Plasmid transfection in HEK293T cells was performed using the ThermoFisher
955 Lipofectamine 2000 transfection reagent. HEK293T cells seeded on a 6 well plate and
956 transfected with 4ug of plasmid. Cells were lysed using Modified RIPA buffer 72 days
957 post-transfection, and the lysate was spun down at 10,000g in a microcentrifuge and
958 supernatant was harvested. Empty vector, WT, and R230G protein was then quantified
959 using the Pierce BCA Assay kit (Thermo Scientific #23225), and 10 µg protein lysate
960 was diluted in 4X SDS-PAGE Loading Buffer supplemented with 10% β-
961 mercaptoethanol (Sigma #M3148) and loaded into each well of an Any kDa Bio-Rad
962 Mini-PROTEAN TGX [4569031] gel, and run for 30 minutes at 150 V. Proteins were
963 then transferred onto a nitrocellulose membrane [Sigma #IPVH00010] and blocked with
964 5% BSA (Sigma #A9418) in TBST (blocking buffer) for 1 hour at room temperature. The
965 membrane was then blotted with 1:1000 Anti-HA (#sc-805) and 1:5000 Anti-alpha-
966 tubulin (Sigma #T6074) primary antibody in blocking buffer overnight at 4°C under
967 constant rocking. The following day the membrane was washed 4 times in TBST for 10
968 minutes, followed by 1 hour incubation in a 1:10000 anti-mouse (#715-035-150) and anti-
969 rabbit (#711-036-152) HRP-conjugated secondary antibody in blocking buffer at room
970 temperature. The membrane was then washed again for 4 times in TBST for 10 minutes,
971 after which the membrane was treated with Pierce ECL Western solution for HRP
972 detection (Thermo Scientific #32106) for 5 minutes at room temperature. The membrane
973 was then transferred into a clear plastic cover and imaged using a chemiluminescence
974 detector (Biotechnology #92-14860). Quantification of protein band intensity was
975 accomplished using the ImageJ band densitometry plugin, and final plots were created
976 using Prism.

977

978 ***CLIP2***

979 *Western blot*

980 HEK293T cells were transfected with pEGFP-CLIP2 WT, R349C (TGC or TGT) either
981 with constitutively active AKT pE17K (Addgene #73050) or empty vector using
982 Lipofectamine as previously described, lysed into sample buffer, and analyzed by
983 western using anti-GFP antibody (1:200 Thermo Scientific #GF28R).

984

985 *Microtubule analysis*

986 HuH7 cells cultured in DMEM with 10% fetal calf serum (Sigma) and 1% antibiotic-
987 antifungal mixture (Gibco) were transfected with pEGFP-CLIP2 WT, R349C or S352A
988 (Turbofect, ThermoFisher Scientific #R0531). Time-lapse sequences ($\Delta t = 2.4$ s, 80 frames)
989 of the CLIP2 fluorescence signal were captured using a Leica DMLB microscope through
990 a 100x 1.3 NA objective and a Scion CFW1312M camera. The parameters of microtubule
991 dynamics were computed as previously described⁷⁵. Statistical comparisons were
992 performed using one-factor ANOVA.

993 ***PLCE1***

994 *Cell transfection and lysis*

995 Plasmid expressing PLCE1 including the WT, p.E521Q, and p.E623Q mutations were
996 transfected into HEK293 cells and were maintained in DMEM supplemented with 10%
997 FBS and 1% penicillin/streptomycin. Plasmids were transfected into HEK293 cells using
998 Lipofectamine (Invitrogen), grown for 48 hr and lysed in lysis buffer (1% Triton X-100,
999 50 mM Tris pH 7.4, 10 mM MgCl₂, 500 NaCl) with added protease inhibitors (Roche).
1000 The lysates were spun down at 20000 g/4°C/15 min and the supernatants were used for
1001 overnight incubation with 20 µl of GST beads containing GST recombinant proteins on
1002 the rotator. After the incubation samples were washed with 800 µl lysis buffer, the GST
1003 beads were collected at 500 g/4°C/2 min, the supernatants were aspirated out and this
1004 washing was repeated 3 times. Proteins were eluted with 20 µl of 2x Laemmli buffer.
1005

1006 *Pulldown assay*

1007 Eluted proteins were diluted in 4X SDS-PAGE Loading Buffer supplemented with 10%
1008 β-mercaptoethanol (Sigma #M3148) and loaded into each well of an Any kDa Bio-Rad
1009 Mini-PROTEAN TGX gel, and run for 30 minutes at 150 V, samples transferred to
1010 PVDF membrane (Sigma #IPVH00010), blocked with 5% BSA (Sigma #A9418) in
1011 TBST for 1h at RT, membrane blotted with 1:1000 anti-RAC1, 1:1000 anti-CDC42,
1012 1:1000 anti-RHOA, and 1:1000 anti-Myc, washed in TBST for 10min then blotted with
1013 1:10000 anti-mouse (#715-035-150) and anti-rabbit (#711-036-152) HRP-conjugated
1014 antibody, washed in TBST for 10m, then developed in Pierce ECL Western solution
1015 (Thermo Scientific #32106) for 5min, and imaged using a chemiluminescence detector
1016 [Biotechnology #92-14860], and band intensity quantified using ImageJ band
1017 densitometry, and plotted using Prism.
1018

1019 The GST-PAK1 beads (#PAK02-A) and GST-rhotekin RBD beads (#RT02-A) were
1020 purchased from Cytoskeleton. Anti-Myc (#2278; Cell Signaling Tech.), anti-RhoA
1021 (#2117; Cell Signaling Tech.), anti-Rac1 (#610650; BD Transduction Labs), anti-Cdc42
1022 (#610928; BD Transduction Labs) were purchased from the indicated commercial
1023 sources.
1024

1025 ***BRSK2 Western Blot***

1026 HEK293T cells were transfected with the pEXP-CMV-BRSK2-Flag plasmid containing
1027 wildtype, K48A kinase-dead mutant, and R620H patient mutation BRSK2 sequence
1028 using PEI (Sigma Millipore #919012) and OptiMEM (Gibco #31985-070) according to
1029 the manufacturer's guidelines. Protein concentration of lysates was measured using the
1030 Pierce BCA Protein Assay Kit (Thermo Scientific #23225), then 20 µg of protein was
1031 loaded into each well of a 4-12% Bis-Tris Gel (Invitrogen #NP0336), transferred to
1032 nitrocellulose membranes (Thermo, #88018), blocked then blotted with one of the
1033 following primary antibodies: 1:1000 Flag rabbit (Cell Signaling Technology #14793S),
1034 1:1000 Beta-actin rabbit (Sigma #A5316), 1:1000 anti-Phospho-AMPK Substrate Motif
1035 rabbit (Cell Signaling Technology #5759) and 1:1000 mTOR rabbit (Cell Signaling
1036 Technology #2983), 1:1000 P-mTOR Ser 2448 rabbit (Cell Signaling Technology
1037 #5536), 1:1000 p70 S6 Kinase rabbit (Cell Signaling Technology #34475), 1:1000
1038 Phospho-p70 S6 Kinase Thr 389 rabbit (Cell Signaling Technology #9234), 1:1000 4E-
1039 BP1 rabbit (Cell Signaling Technology #9644) and 1:1000 Phospho-4E-BP1 Thr 37/46

1040 rabbit (Cell Signaling Technology #2855) at 4°C overnight, rinsed in TBST for 10
1041 minutes, incubated with LI-COR IRDye 680 Donkey anti-Mouse or 800 Donkey anti-
1042 Rabbit (LI-COR #926-68072, #926-32213) 1:10,000 rinsed in TBST and imaged on an
1043 Odyssey CLx using Image Studio software for analysis of band intensity.

1044

1045 ***Xenopus* modeling**

1046 *Xenopus* embryo manipulations were conducted according to established protocols⁷⁶.
1047 Female adult *Xenopus laevis* were induced to ovulate by the injection of human chorionic
1048 gonadotropin, and *in vitro* fertilization was performed by homogenizing a small piece of
1049 a testis. Embryos were dejellied in 1/3 X Marc's Modified Ringer's (MMR) with 2.5%
1050 (w/v) cysteine (pH7.9) at the 2-cell stage and were microinjected with either gene-
1051 specific MO or mock into two dorsal blastomeres at the 4-cell stage in 2% Ficoll (w/v) in
1052 1/3 X MMR. Injected embryos were incubated at 18°C until stage 19 and fixed with 1X
1053 MEMFA (0.1 M MOPS, 2mM EGTA, 1 mM MgSO₄, 3.7% formaldehyde, pH 7.4). The
1054 gene sequence for *Xenopus* Whamm was obtained from Xenbase
1055 (<http://www.xenbase.org>). A Morpholino antisense oligonucleotide (MO) against
1056 Whamm was designed to block mRNA splicing (Gene Tools) 5' –
1057 AAAAGTAGGAAGAAGCCCCACCCT -3'. The Whamm open reading frame was
1058 amplified from *Xenopus* cDNA and cloned into the pCS10R MCC vector containing GFP
1059 tag. Capped mRNA was synthesized using the mMESSAGING mMACHINE SP6
1060 transcription kit (Invitrogen Ambion, cat# AM1340), and injected to assess rescue. To
1061 measure the distance of the neural folds, *in situ* hybridization against Pax3 was performed
1062 as previously described⁷⁶. Images were captured using a ZEISS Axio Zoom V16
1063 stereomicroscope and associated Zen software, and neural folds visualized by pax3 were
1064 analyzed in Fiji. To verify the efficiency of MO, MO was injected into all cells at the 4-
1065 cell stage, and total RNAs were extracted from four embryos using the TRIZOL reagent
1066 (Invitrogen, cat # 15596026). cDNAs were synthesized using M-MLV reverse
1067 Transcriptase (Invitrogen, cat#28025013) and random primers (NEB, cat#S1330S).
1068 cDNAs were amplified by Taq polymerase (NEB, cat# M02735) using the following
1069 primers: 5'-CGGTGCAGGACTTGGATTAT-3', 5'-
1070 CCCATTTAGCTACCTCCTTCTG-3'.

1071

1072 **Data Availability**

1073 Exome and genome sequencing data are available in publicly accessible databases for the
1074 1,576 subjects enrolled after inclusion of dbGaP language into the consenting process/
1075 became standard. These data are at dbGaP (accession #phs002591.v1.p1,
1076 phs000744.v5.p2 (Yale Mendelian Sequencing Center), Kids First: Whole Genome
1077 Sequencing in Structural Defects of the Neural Tube Accession (phs002591.v1.p1).
1078 Sequencing data on the remaining 743 subjects is available upon request.
1079

1080 **Code Availability**

1081 Computational codes used in this study are available in GitHub
1082 (https://github.com/Gleeson-Lab/Publications/tree/main/MM_DNM).
1083

1084 **Acknowledgement**

1085 We especially thank the families and the individuals with meningomyelocele that
1086 participated in this study, Kiely James, Renee George, Brett Copelande, Valentina
1087 Stanley, Celine Shen, and Jennifer Venneri from the Spina Bifida Sequencing
1088 Consortium, the Spina Bifida Association, the UCSD Laboratory for Pediatric Brain
1089 Disease for clinical and technical support, Brin Rosenthal and Katie Fisch from the
1090 UCSD Altman Clinical and Translational Research Institute for statistical modeling,
1091 Broad Institute, Yale Genetic Center, Regeneron Genetics Center, UCSD Institute for
1092 Genomic Medicine, UC Irvine Sequencing Center and Rady Children Institute for
1093 Genomics Medicine for sequencing support, Barbara Craddock from Stony Brook
1094 University for functional analysis of TNK2, and the Spina Bifida Association for
1095 recruitment efforts.
1096

1097 **Funding**

1098 This work was supported by the Center for Inherited Disease Research grant
1099 HHSN268201700006I, the Yale Center for Genomic Analysis, the Broad Institute, the
1100 UC Irvine Genomics Core, the UCSD Institute for Genomic Medicine, the UCSD
1101 Imaging Core, X01HD100698, X01HD110998, HD114132, P01HD104436,
1102 U54OD030187, and support from the Howard Hughes Medical Institute and Rady's
1103 Children Institute for Genomic Medicine to JGG. YJH and SK were supported by the
1104 National Research Foundation of Korea funded by the Ministry of Science and ICT
1105 (MSIT) (RS-2023-00277314). WTM was supported by VA Merit Award # I01
1106 BX006248.
1107

1108 **Spina Bifida Sequencing Consortium members**

1109 Dr. Allison Elizabeth Ashley Koch, PhD (Duke University), Dr. Kit Sing Au, PhD and
1110 Dr. Hope Northrup, MD (University of Texas, Houston), Dr. Gyang Markus Bot, MD
1111 (Jos University Teaching Hospital, Jos, Nigeria), Valeria Capra, MD (IRCCS Istituto
1112 Giannina Gaslini, Italy), Dr. Richard H. Finnell, PhD, DABMGG (Baylor College of
1113 Medicine), Dr. Zoha Kibar, PhD (Université de Montréal, Canada), Dr. Philip J. Lupo,
1114 PhD, MPH (Baylor College of Medicine), Dr. Helio R. Machado, MD (University of Sao
1115 Paulo, Brazil), Dr. Tony Magana, MD (Mekelle University, Mekelle, Ethiopia), Dr. Rony
1116 Marwan, MD (University of Colorado), Dr. Gia Melikishvili, MD (MediClub Georgia,

1117 T'bilisi, Georgia), Dr. Osvaldo M. Mutchinick, MD, PhD (Salvador Zubirán National
1118 Institute of Health Sciences and Nutrition, Mexico City, Mexico), Dr. Roger E.
1119 Stevenson, MD (Greenwood Genetic Center), Dr. Anna Yurrita, MD (Francisco
1120 Marroquín University, Guatemala City, Guatemala), Dr. Maha S. Zaki, MD, PhD
1121 (National Research Center, Cairo, Egypt), Dr. Sara Mumtaz, PhD (National University of
1122 Medical Sciences, Rawalpindi, Pakistan), Dr. José Ramón Medina-Bereciartu, MD
1123 (Venezuela Association of Spina Bifida, Caracas, Venezuela), Dr. Friedhelm Hildebrandt
1124 (Boston Children's Hospital, Harvard Medical School), Dr. Caroline M. Kolvenbach, MD
1125 (Boston Children's Hospital, Harvard Medical School), Shirlee Shril, MS (Boston
1126 Children's Hospital, Harvard Medical School), Dr. Mahmoud M. Noureldeen, MD and
1127 Dr. Aida MS. Salem, MD (Beni-Suef University, Beni-Suef, Egypt), Dr. Joseph Gleeson,
1128 MD (UC San Diego).

1129

1130 **Author Contributions**

1131 Y-JH, CW, NM FJ, KIV, CB, SL, NJ, AP recruited subjects and performed genetic
1132 analysis. IJ performed MERFISH analysis, CJL and JBW generated *Xenopus* data. AN,
1133 J-EL, IT, FAB, KFT, SY, HJ, BB WTM, CH, SAM, HYG, BB, CP performed functional
1134 analysis, ZK GMB, HN, KSU, MS, AA-K, RHF, JL, HM, CA, HRM, RES, AY, SM,
1135 OMM, JRM-B, FH, GM, RM, VC, MMN, AMSS, MYI, MSZ recruited families. AA,
1136 ARS, SWK, performed sequencing. Y-JH, SK and JGG performed analysis, wrote drafts,
1137 and incorporated feedback from coauthors.

1138

1139 **Competing interests**

1140 AA and ARS are full time employees of Regeneron Genetics Center. SK is cofounder of
1141 AIMA Inc., which seeks to develop techniques for early cancer diagnosis based on
1142 circulating tumor DNA.

1143

1144 **Additional Information**

1145 Supplementary Information is available, containing Supplementary Table and
1146 Supplementary Notes.

1147

1148 **Method references**

1149


- 1150 52 Rendeli, C. *et al.* Assessment of health status in children with spina bifida. *Spinal*
1151 *Cord* **43**, 230-235 (2005). <https://doi.org/10.1038/sj.sc.3101707>
- 1152 53 Dimitromanolakis, A., Paterson, A. D. & Sun, L. Fast and accurate shared
1153 segment detection and relatedness estimation in un-phased genetic data via
1154 TRUFFLE. *Am J Hum Genet* **105**, 78-88 (2019).
1155 <https://doi.org/10.1016/j.ajhg.2019.05.007>
- 1156 54 Lee, J. *et al.* Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for
1157 genomic, transcriptional and epigenomic signatures. *Nucleic Acids Res* **46**, W102-
1158 W108 (2018). <https://doi.org/10.1093/nar/gky406>
- 1159 55 Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing
1160 genomic features. *Bioinformatics* **26**, 841-842 (2010).
1161 <https://doi.org/10.1093/bioinformatics/btq033>

- 1162 56 Dong, C. *et al.* Comparison and integration of deleteriousness prediction methods
1163 for nonsynonymous SNVs in whole exome sequencing studies. *Hum Mol Genet*
1164 **24**, 2125-2137 (2015). <https://doi.org/10.1093/hmg/ddu733>
- 1165 57 Ioannidis, N. M. *et al.* REVEL: An ensemble method for predicting the
1166 pathogenicity of rare missense variants. *Am J Hum Genet* **99**, 877-885 (2016).
1167 <https://doi.org/10.1016/j.ajhg.2016.08.016>
- 1168 58 Jaganathan, K. *et al.* Predicting splicing from primary sequence with deep
1169 learning. *Cell* **176**, 535-548 e524 (2019).
1170 <https://doi.org/10.1016/j.cell.2018.12.015>
- 1171 59 Giacobuzzi, E., Popitsch, N. & Taylor, J. C. GREEN-DB: a framework for the
1172 annotation and prioritization of non-coding regulatory variants from whole-
1173 genome sequencing data. *Nucleic Acids Res* **50**, 2522-2535 (2022).
1174 <https://doi.org/10.1093/nar/gkac130>
- 1175 60 Suvakov, M., Panda, A., Diesh, C., Holmes, I. & Abyzov, A. CNVpytor: a tool
1176 for copy number variation detection and analysis from read depth and allele
1177 imbalance in whole-genome sequencing. *Gigascience* **10** (2021).
1178 <https://doi.org/10.1093/gigascience/giab074>
- 1179 61 Chen, X. *et al.* Manta: rapid detection of structural variants and indels for
1180 germline and cancer sequencing applications. *Bioinformatics* **32**, 1220-1222
1181 (2016). <https://doi.org/10.1093/bioinformatics/btv710>
- 1182 62 Rausch, T. *et al.* DELLY: structural variant discovery by integrated paired-end
1183 and split-read analysis. *Bioinformatics* **28**, i333-i339 (2012).
1184 <https://doi.org/10.1093/bioinformatics/bts378>
1185 <https://github.com/brentp/smoove>.
- 1186 64 Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S. & Zhuang, X. RNA
1187 imaging. Spatially resolved, highly multiplexed RNA profiling in single cells.
1188 *Science* **348**, aaa6090 (2015). <https://doi.org/10.1126/science.aaa6090>
- 1189 65 Delile, J. *et al.* Single cell transcriptomics reveals spatial and temporal dynamics
1190 of gene expression in the developing mouse spinal cord. *Development* **146** (2019).
1191 <https://doi.org/10.1242/dev.173807>
- 1192 66 Soldatov, R. *et al.* Spatiotemporal structure of cell fate decisions in murine neural
1193 crest. *Science* **364** (2019). <https://doi.org/10.1126/science.aas9536>
- 1194 67 Simoes-Costa, M. & Bronner, M. E. Establishing neural crest identity: a gene
1195 regulatory recipe. *Development* **142**, 242-257 (2015).
1196 <https://doi.org/10.1242/dev.105445>
- 1197 68 Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene
1198 expression data analysis. *Genome Biol* **19**, 15 (2018).
1199 <https://doi.org/10.1186/s13059-017-1382-0>
- 1200 69 Rosenthal, S. B. *et al.* Mapping the common gene networks that underlie related
1201 diseases. *Nat Protoc* **18**, 1745-1759 (2023). [https://doi.org/10.1038/s41596-022-](https://doi.org/10.1038/s41596-022-00797-1)
1202 [00797-1](https://doi.org/10.1038/s41596-022-00797-1)
- 1203 70 Huang, J. K. *et al.* Systematic evaluation of molecular networks for discovery of
1204 disease genes. *Cell Syst* **6**, 484-495 e485 (2018).
1205 <https://doi.org/10.1016/j.cels.2018.03.001>

- 1206 71 Duman, R. S., Sanacora, G. & Krystal, J. H. Altered connectivity in depression:
1207 GABA and glutamate neurotransmitter deficits and reversal by novel treatments.
1208 *Neuron* **102**, 75-90 (2019). <https://doi.org/10.1016/j.neuron.2019.03.013>
1209 72 Tolia, K. F. *et al.* The Rac1-GEF Tiam1 couples the NMDA receptor to the
1210 activity-dependent development of dendritic arbors and spines. *Neuron* **45**, 525-
1211 538 (2005). <https://doi.org/10.1016/j.neuron.2005.01.024>
1212 73 Komatsu, N. *et al.* Development of an optimized backbone of FRET biosensors
1213 for kinases and GTPases. *Mol Biol Cell* **22**, 4647-4656 (2011).
1214 <https://doi.org/10.1091/mbc.E11-01-0072>
1215 74 Duman, J. G. *et al.* The adhesion-PCR BAI1 shapes dendritic arbors via Bcr-
1216 mediated RhoA activation causing late growth arrest. *Elife* **8** (2019).
1217 <https://doi.org/10.7554/eLife.47566>
1218 75 Henrie, H. *et al.* Stress-induced phosphorylation of CLIP-170 by JNK promotes
1219 microtubule rescue. *J Cell Biol* **219** (2020). <https://doi.org/10.1083/jcb.201909093>
1220 76 Sive, H., Grainger, Robert M, and Harland, Richard M. *Early development of*
1221 *Xenopus Laevis: a laboratory manual.*, (2000).
1222 77 Samocha, K. E. *et al.* A framework for the interpretation of de novo mutation in
1223 human disease. *Nat Genet* **46**, 944-950 (2014). <https://doi.org/10.1038/ng.3050>
1224 78 Misra, S. N. & Kearney, J. A. Alphabet Soup: Recurrent de novo mutations in
1225 novel genes causing developmental and epileptic Ecephalopathies. *Epilepsy Curr*
1226 **18**, 125-127 (2018). <https://doi.org/10.5698/1535-7597.18.2.125>
1227 79 Homsy, J. *et al.* De novo mutations in congenital heart disease with
1228 neurodevelopmental and other congenital anomalies. *Science* **350**, 1262-1266
1229 (2015). <https://doi.org/10.1126/science.aac9396>
1230 80 Ianevski, A., Giri, A. K. & Aittokallio, T. Fully-automated and ultra-fast cell-type
1231 identification using specific marker combinations from single-cell transcriptomic
1232 data. *Nat Commun* **13**, 1246 (2022). <https://doi.org/10.1038/s41467-022-28803-w>
1233 81 Ten Klooster, J. P. *et al.* Interaction between Tiam1 and the Arp2/3 complex links
1234 activation of Rac to actin polymerization. *Biochem J* **397**, 39-45 (2006).
1235 <https://doi.org/10.1042/BJ20051957>
1236 82 Yoo, S., Kim, Y., Lee, H., Park, S. & Park, S. A gene trap knockout of the Tiam-1
1237 protein results in malformation of the early embryonic brain. *Mol Cells* **34**, 103-
1238 108 (2012). <https://doi.org/10.1007/s10059-012-0119-x>
1239 83 Zhao, L. *et al.* Bhlhe40/Sirt1 axis-regulated mitophagy is implicated in all-trans
1240 retinoic acid-induced spina bifida aperta. *Front Cell Dev Biol* **9**, 644346 (2021).
1241 <https://doi.org/10.3389/fcell.2021.644346>
1242

1243 **Extended Data Figure**

1244




1245

1246 **Extended Data Figure 1. Power calculation of estimating a cohort size for DNM**

1247 **detection.** Power calculation showing potential number of discovered genes compared
1248 with cohort size (350 trios), for two different v values (enrichment ratio of loss of
1249 function variants in case versus control) and two different k values (assumed number of
1250 risk genes). For instance, if there are 50 genes to discover (k=50), a cohort of 400 trios
1251 will identify 16 genes if LOF variants are 2.5x more common in affected (v=2.5). All
1252 calculations manage a conservative false discovery rate (FDR). Gray dash: FDR.

1253


1254



1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266

Extended Data Figure 2. Quantitative and qualitative features of de novo variants. **a-b**, Mutational signatures of DNMs showing known de novo signatures 1 and 5, in both **(a)** MM and **(b)** control cohorts. 1,251 and 1,035 SNVs were utilized for the signature analysis. **c-d**, DNM counts per proband following Poisson distribution, examined based on cutoffs (DNM count per proband) ranging from 1 to 20. **(c)** Chi-Square goodness-of-fit (two sided) was performed with an expected Poisson distribution with **(d)** lambda as an average DNM count per proband, for all cutoffs (see **Methods**). **e**, DNM rates for all, coding, and noncoding regions. Observed and theoretical DNM rates are marked in the left and right y-axis, respectively. Theoretical rate calculated by normalization of the variant rate with the total size of hg38 coding region (59,281,518 bp). *P* values were calculated by a two-sided Wilcoxon rank-sum test. ns: not significant.

1267



1268

1269

Extended Data Figure 3. Quantitative and qualitative features of de novo variants.

1270

a, Age of conception of father and mother in MM ($n = 79$) and control ($n = 683$) trios.

1271

The ages of conception were compared with Wilcoxon rank-sum test (two sided). The

1272

age of conceptions were significantly higher in controls than MM, for both of the parents.

1273

P values: **** < 0.0001 .

1274

b, De novo large CNVs (> 100 kb) detected from WGS. Read



1275

depths of proband, father, and mother shown. Gray lines: read depths. Green lines: copy


1276

number.


1277




1278
1279



1280




1281




1282

1283 **Extended Data Figure 4. Spatial expression of DNM genes with MERFISH.** Spatial
1284 expression of the 36 MM genes with damaging DNMs. **a**, Gene expression of marker
1285 genes for seven selected cell types (neuron, neural progenitor, pre-epithelial to
1286 mesenchymal transition neural Crest progenitor (NC progenitor), neural crest, mesoderm,
1287 dorsal root ganglia, and blood), in seven embryonic replicates (regions) 1 (top)-7
1288 (bottom). **b**, Spatial expression pattern of 36 damaging DNM genes. The seven replicates
1289 (X axes) of mouse E10.5 showing the gene expression pattern of candidate genes (Y
1290 axes). R=Rostral, C=Caudal, V=Ventral, D=Dorsal.




1291

1292 **Extended Data Figure 5. Cell type expression of the DNM genes in MERFISH. a,**
 1293 Expression of the 36 damaging DNMs in seven cell types: neuron, neural progenitor, pre-
 1294 epithelial to mesenchymal transition neural crest progenitor (Pre-EMT-NCP), neural
 1295 crest, mesoderm, dorsal root ganglia, and blood. Indeterminate refers to the cells that
 1296 were not specified with the marker genes designed for the seven cell types. **b,** Expression
 1297 of marker genes used for specifying the cell types in MERFISH. Marker genes are shown
 1298 within the cell type category which they represent.



1299
1300

1301 **Extended Data Figure 6. Connections of genes having damaging DNMs of MM and**
 1302 **control cohorts. a-b,** Genes with damaging DNMs (LGD + D-Mis) and their
 1303 interconnections based on the STRING database, are shown for **(a)** MM and **(b)** control
 1304 cohorts. Node color: variant functional categories: LGD (purple), D-Mis (light pink), and
 1305 D-Mis-HC (dark pink). Doubleton genes: black borders. Edge thickness: confidence
 1306 score of the protein interaction.




1315

1316

1317 **Extended Data Figure 8. pLI comparison of DNM and propagated genes from the**
1318 **five submodules.** The probabilities of being loss of function intolerant (pLI) of genes
1319 from the five functional submodules are shown, derived from 46 damaging DNMs and 51
propagated genes. Black thick line: median, Box: 1st and 3rd quantiles.

1320



1321

1322

1323


1324

1325

1326

1327


Extended Data Figure 9. The P168L patient mutation impairs TNK2 activity. a, P168L mutation is located within the kinase domain. TNK2 contains sterile alpha motif (SAM), Src homology 3 (SH3), CDS42, and RAC-interactive binding (CRIB), Mig6 homology region (MHR), and ubiquitin-associated domain (UBA). **b,** Blots for the A156T kinase dead, wild-type, and the patient mutation P168L. Lysates were probed with pY284-Ack1 (top), Ack1-flag (middle), and gamma-tubulin (bottom).



1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339

Extended Data Figure 10. The H1149P patient mutation impairs TIAM1 activity. **a**, H1149P mutation is located within the Dbl homology (DH) domain responsible for GEF activity. TIAM1 contains an N-terminal pleckstrin homology (PH), coiled-coiled (CC), extension (Ex), RAS binding (RBD), PDZ, Dbl-homology (DH) and PH domains, with the patient mutation falling within the DH domain. **b**, Construct expression H1149P is equivalent to wildtype in Phalloidin quantification. **c-d**, Construct expression H1149P in (c) basal and (d) constitutive active (C.A.) Src Rac1 Förster resonance energy transfer (FRET) is equivalent to wildtype. **e**, Protein expression H1149P in C.A. Src Rac1 FRET is equivalent to wildtype. Bar: mean, Errorbar: standard deviation of mean (SEM). Kruskal-Wallis followed by a pairwise Wilcoxon test, *P* value adjusted with Bonferroni. Data shown with Hampel filter.

1340




1341

1342

1343

1344 **Extended Data Figure 11. *VWA8b* patient mutation R230G significantly reduces**
1345 **protein expression levels.** **a**, Schematic of protein domains for VWA8b consisting of
1346 NTPase, Walker A (WA), ATP binding, and Walker B (WB) domain and patient
1347 mutation R230G in the NTPase domain. **b**, Western blot for HA-tagged mVwa8b empty
1348 vector (EV), wildtype and p.R230G protein overexpressed in HEK293T cells and stained
1349 for HA and alpha tubulin as loading control. **c**, Quantification of HA band intensity from
1350 panel **b** normalized to loading control. Bar: mean, Errorbar: standard deviation of mean
1351 (SEM). one-way ANOVA ****: P value < 0.0001.


1351




1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367

Extended Data Figure 12. The R349C patient mutation in *CLIP2* has no observable effect on microtubule dynamics. **a**, Domains in CLIP2 protein, microtubule associated domain (MBD), serine rich region containing the R349C patient mutation, and coiled coil domain. **b**, GFP fused CLIP2 expression in HEK293T cells for wildtype (WT) and two synonymous codons (TGC and TGT both encoding for CYS) for R349C patient mutation. No notable difference in the level of expression was detected between the WT and the mutants. Experiments included co-transfection with constitutively active AKT E17K, a presumed upstream kinase of nearby S352. **c-f**, While at a low expression level in HuH7 cells, fluorescent CLIP2 is restricted to growing microtubule plus ends as expected (not shown), **(c)** its mild overexpression highlights the whole microtubule bodies without difference between WT, R349C (TGC) and a putative phosphorylation site, S352A (Scale bar 10 μ m). This condition allowed the measurement of a complete panel of microtubule dynamic instability parameters: **(d)** growth and shrinkage speed, **(e)** catastrophe and rescue (R) frequencies **(f)** the time spent in pause. There was no statistical difference between CLIP2 WT and the mutants. The values were measured

1368 from at least 125 microtubules (25 cells) per condition. n = 3 independent experiments.
1369 Bar: mean, Point: data for each microtubule, Errorbar: standard deviation.
1370
1371



1372
1373
1374 **Extended Data Figure 13. *BRSK2* patient mutation R620H shows no notable defects**
1375 **in kinase activity across known downstream phosphorylation targets. a,** R620H
1376 mutation is located within the kinase associated 1 domain (KA1). *BRSK2* also contains a
1377 kinase domain, Ubiquitin-associated (UBA), Proline rich region (Pro R). **b,** Western blot
1378 showing phosphorylation of AMPK substrate motifs observed across wildtype (WT),
1379 kinase dead mutant control (K48A) and patient mutation (R620H) Flag-tagged *BRSK2*
1380 when expressed in HEK293T cells. K48A has an average reduced intensity that is not
1381 observed in R620H. **c,** Western Blots of total and phosphorylated mTOR, S6K and
1382 4EBP1 substrates showing no notable differences in phosphorylation for patient mutation
1383 R620H.



1384

1385

1386

1387

1388

1389

1390

1391

1392

1393

1394

1395

Extended Data Figure 14. *PLCE1* patient mutation E623Q does not lead to

diminished Rho GTPase activity. **a**, Schematic of *PLCE1* protein with domains

annotated. Patient E623Q mutation is located in the Ras GEF domain. *PLCE1* contains a

Guanine nucleotide exchange factor for Ras-like small GTPases (RAS GEF), Pleckstrin

Homology (PH), Phospholipase C catalytic domain X (PLCX), Phospholipase C catalytic

domain Y (PLCY), Protein Kinase C conserved region 2 (C2), RAS association domain 1


(RA1), and RAS association domain 2 (RA2). **b**, Active GTP-bound forms of RAC1 and

CDC42 precipitated from HEK293 expressing Myc-tagged *PLCE1* using a GST-PAK1

pull-down assay (n=4). Five percent input represents the controls for equal loading.


Compared to mock cells, overexpression of wild-type (WT) and variant forms of *PLCE1*

1396 exhibited no significant difference in RAC1 and CDC42 activity. **c-d**, Quantifications of
1397 (c) RAC1 and (b) CDC42. **e**, Active GTP-bound form of RHOA precipitated from
1398 HEK293 expressing Myc-tagged PLCE1 using a GST-rhotekin pulldown assay.
1399 Overexpression of WT PLCE1 resulted in a substantial decrease in relative RHOA
1400 activity compared with mock cells. Compared to WT, cells transfected with variant forms
1401 of PLCE1 exhibited no significant differences in GTP-bound RHOA. **f**, Quantification of
1402 RHOA (n=4). Data were analyzed by one-way ANOVA with post hoc Bonferroni
1403 correction. Error bars: standard deviation for greater than 3 independent experiments. PD;
1404 pulldown, ** P < 0.01, n.s. not significant.



1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416

Extended Data Fig. 15. Validation of Whamm morpholino antisense oligonucleotide (MO). **a**, RT-PCR validates the effective disruption of splicing following injection of Whamm MO. **b-d**, The neural tube closure defect phenotype induced by Whamm MO (10 ng) was rescued through the injection of Whamm mRNA (700 pg). Embryos injected only with mRNA showed no significant phenotype. **b**, Dorsal views of *Xenopus* embryos at Stage 19 **c**, Embryos subjected to in situ hybridization against Pax3 to visualize the neural folds **d**, Graph depicting the quantitative analysis of the distance between neural folds. P-values by one-way ANOVA with post-hoc honestly significant difference (HSD) test. ****: *P* value < 0.0001, ns: not significant.



1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431

Extended Data Figure 16. Pipeline of detecting high-confidence de novo mutation (DNM) and annotation of D-Mis-HC. **a**, Schematic overview of DNM detection. The raw coverages of aligned bam files were utilized in consensus region generation (see Methods). Germline variants were utilized to test the integrity of the trios with TRUFFLE. GATK genotype refinement workflow was utilized for the DNM detection **b**, The candidate de novo SNVs and Indels were applied with a series of qualitative and quantitative filters. DP: depth, Binom: binomial test, alt: count of reads with alternative alleles, GQ: genotype quality, MQ: mapping quality, VQSR: variant quality score recalibration, GT: genotype. **c-d**, Pathogenicity prediction of D-Mis-HC variants with MetaLR and REVEL. The pathogenicity of 116 D-Mis DNMs predicted by MetaSVM are shown with the prediction results from MetaLR and REVEL. **(c)** MetaLR deleterious (score > 0.5) is shown in triangle and **(d)** mutations with REVEL score higher than 0.75 are predicted as deleterious (right).

1432 **Extended Data Table**

Mutation type	Category	Coding	Noncoding	Total
SNV + Indel	DNM count	1,976	8,817	10793
	DNM count per proband	20.16	89.97	110.13
	rate ($\times 10^{-8}$)	0.315	1.4	1.72
SNV	DNM count	1,658	7,429	9,087
	DNM count per proband	16.92	75.81	92.72
	rate ($\times 10^{-8}$)	0.26	1.18	1.45
Indel	DNM count	318	1,388	1,706
	DNM count per proband	3.24	14.16	17.41
	rate ($\times 10^{-8}$)	0.05	0.22	0.27

1433 **Extended Data Table 1. De novo SNV and Indel rates ($\times 10^{-8}$) of WGS in coding and**
1434 **noncoding regions.** Rates were calculated with 99 trios could be analyzed after removal
1435 of four kinship failed trios.
1436

Family	Chromosome	Start position	End position	Length	Variant type	Cytoband
7646	chr22	20,400,001	21,100,001	-700,000	Deletion	q11.21
7647	chr15	72,700,001	75,800,001	-3,100,000	Deletion	q24.2-q24.1
7662	chr15	30,600,001	32,100,001	1,500,000	Duplication	q13.3-q13.2
8469	chr21	13,900,001	43,000,001	28,900,000	Duplication	q22.11-q22.12

1437 **Extended Data Table 2. de novo large CNV (>100kb) in WGS, analyzed with 99**
1438 **trios.**

1439

Term	Ontology Source	ID	P Value (Bonferroni step-down adjusted)	% Associated Genes	Nr. Genes	Associated Genes
Morphogenesis of a polarized epithelium	GO Biological Process	GO:0001738	0.00001	8.41	9.00	BRSK2, CELSR1, CELSR2, GRHL3, LAMA3, SCRIB, SH3BP1, SMURF2, TIAM1
Signaling by NTRKs	Reactome	R-HSA:166520	0.00031	5.97	8.00	CLTC, DNM3, EP300, IRS1, PTPRS, RPS6KA2, TCF12, TIAM1
Establishment of planar polarity	GO Biological Process	GO:0001736	0.00070	7.41	6.00	BRSK2, CELSR1, CELSR2, GRHL3, SMURF2, TIAM1
Wnt signaling pathway, planar cell polarity pathway	GO Biological Process	GO:0060071	0.00100	8.62	5.00	CELSR1, CELSR2, GRHL3, SMURF2, TIAM1
L1CAM interactions	Reactome	R-HSA:373760	0.00220	5.04	6.00	CLTC, CNTNAP1, DCX, DNM3, DPYSL2, RPS6KA2
Signaling by NTRK1 (TRKA)	Reactome	R-HSA:187037	0.00276	5.22	6.00	CLTC, DNM3, EP300, IRS1, RPS6KA2, TCF12
Neural tube closure	GO Biological Process	GO:0001843	0.00323	4.90	5.00	CELSR1, GRHL2, GRHL3, SCRIB, TBXT

1440 **Extended Data Table 3. Pathway enrichment of the damaging DNMs in MM.** 187
 1441 damaging DNMs (LGD + D-Mis) were tested for enrichment in known functional
 1442 biological pathways in Gene ontology (GO) Biological Process, Reactome, and KEGG
 1443 pathways. Pathways that were significant with Bonferroni step-down adjusted P value <
 1444 0.05 are shown.

1445 Supplementary Table

Family ID	Gene	Mutation	OMIM associated phenotype	Mutations reported with OMIM phenotype	Patient phenotype
5875	<i>KIF22</i>	chr16:29798687C>T; c.484C>T; p.Arg162Ter	Spondyloepimetaphyseal dysplasia s. with joint laxity, type 2	Heterozygous missense in exon 4	Excluded Spondyloepimetaphyseal dysplasia features
6032	<i>CELSR1</i>	chr22:46397819G>GTTGGT; c.5551_5555dup; p.Asn1852LysfsTer7	Lymphatic malformation 9 s.	Heterozygous nonsense or frameshift show incomplete penetrance	Excluded lymphatic malformation features
6147	<i>SLCO1B3-SLCO1B7</i>	chr12:21067374C>T, c.1803C>T; p.Arg580X	Digenic recessive hyperbilirubinemia, Rotor type s.	Read through transcript	Excluded hyperbilirubinemia features
6293	<i>TOP2B</i>	chr3:25636033A>G, c.c.740T>C; p.Leu247Pro	B-cell immunodeficiency, distal limb anomalies, and urogenital malformation s.	Heterozygous deletion and missense mutations in the TOPRIM domain	Excluded immunodeficiency, limb and urogenital defect features
6307	<i>ADGRB3</i>	chr6:68975294G>A, c.1688G>A; p.Ser563Asn	Cerebellar ataxia	Biallelic loss	Excluded cerebellar ataxia features
6313	<i>BICRA</i>	chr19:47680692C>T, c.1522C>T; p.Gln508*	Coffin-Siris.-12 s.	Haploinsufficiency	Meets criteria for Coffin-Siris s.
6319	<i>CLIP2</i>	chr7:74357307C>T, c.1045C>T; p.Arg349Cys	Williams-Beuren s.	Contiguous gene deletion s. at 7q11.23	Excluded Williams-Beuren s. features
6328	<i>SLC4A4</i>	chr4:71472901C>A, c.1702C>A; Pro568Thr	Proximal renal tubular acidosis with ocular abnormalities s.	Biallelic substitutions lead to decrease NBC activity	Excluded renal tubular acidosis or ocular features. Displays growth retardation.
6337	<i>TCF12</i>	chr15:57262209G>T, c.412+1G>T; splice loss	Craniosynostosis type 3 s. Hypogonadotropic hypogonadism 26 s.	Haploinsufficiency; Biallelic loss of function	Displays features of craniosynostosis.
6388	<i>LOXHD1</i>	chr18:46509817T>G, c.2067-2A>C splice loss	Deafness, autosomal recessive type 77 s.	Biallelic mutations	Excluded features of deafness
6395	<i>PLA2G7</i>	chr6:46709351G>A, c.845C>T; p.Thr282Ile	Platelet-activating factor acetylhydrolase deficiency s.	Biallelic mutations	Excluded features of platelet-activating factor acetylhydrolase deficiency
6423	<i>KDM1A</i>	chr1:23057487C>T, c.934C>T p.Arg312Cys	Cleft palate and distinctive facial features s.	Heterozygous loss	Lacks features of cleft palate
6570	<i>TNK2</i>	chr3:195872454A>T, c.1462T>A, p.Trp488Arg	Autosomal recessive infantile epilepsy (pending confirmation)	Biallelic loss	Excluded features of infantile epilepsy
6695	<i>TIMM50</i>	chr19:39485743A>G, c.109-2318A>G;	3-methylglutaconic aciduria, type IX s.	Biallelic loss	Excluded features of 3-methylglutaconic aciduria

		p.Tyr143Cys			
6705	<i>ASPM</i>	chr1:197102395T GAGA>T, c.6852_6855delT CTC; p.Leu2285Argfs*6	Microcephaly 5, primary, autosomal recessive s.	Biallelic loss	Excluded features of microcephaly
6708	<i>SCAPER</i>	chr15:76705971G >A, c.2179C>T; p.Arg727Ter	Intellectual developmental disorder and retinitis pigmentosa s.	Biallelic loss	Excluded features of intellectual disability or retinitis pigmentosa
6133	<i>ZSWIM6</i>	chr5:61541917C> T, c.2737C>T; p.Arg913Ter	Acromelic frontonasal dysostosis s.	Haploinsufficiency	Reduced size of nose, possible dysostosis
6289	<i>UNC80</i>	chr2:209872917C >T, c.3793C>T; p.Arg1265Ter	Hypotonia, infantile, with psychomotor retardation and characteristic facies 2 s.	Biallelic loss	Lacks typical facies, but has features of hypotonia
7443	<i>POP1</i>	chr8:98130062G> T, c.571G>T, p.Glu191Ter	Anauxetic dysplasia 2	Biallelic loss	Lacks features of anauxetic dysplasia
7437	<i>DNAH5</i>	chr5:13807727T> G, c.7753-2A>C, splice loss	Ciliary dyskinesia, primary, 3	Biallelic loss	Lacks features of ciliary dyskinesia
7440	<i>ATXN7</i>	chr3:63990756C> T, c.1579C>T; p.Arg527Trp	Spinocerebellar ataxia 7	CAG repeat expansion	Lacks features of spinocerebellar ataxia
8012	<i>MED13L</i>	chr12:115980836 G>A, c.5278C>T; p.Arg1760Ter	ID and distinctive facial features with or without cardiac defects (MRFACD)	Haploinsufficiency	Cannot exclude features of MRFACD.
8055	<i>MMUT</i>	chr6:49444675T> C, c.1640A>G; p.Asn547Ser	Methylmalonic aciduria, mut(0) type	Biallelic loss	Lacks features of methylmalonic aciduria
8012	<i>NCKAP1L</i>	chr12:54499380C >T, c.128C>T; p.Pro43Leu	Immunodeficiency 72 with autoinflammation	Biallelic loss	Lacks features of primary immunodeficiency
7859	<i>VWA8</i>	chr13:41729591T AG>T, c.2587_2588delC T; p.Leu863Sfs*20	Retinitis Pigmentosa 97(?)	Heterozygous missense	Lacks features of retinitis pigmentosa
7821	<i>SPATA16</i>	chr3:173019534C >T, c.800G>A; p.Arg267His	Spermatogenic failure 6 (?)	Biallelic loss	Unable to assess to due female sex
7749	<i>SDHAF1</i>	chr19:35995381T C>T, c.108delC; stop lost	Mitochondrial complex II deficiency, nuclear type 2	Biallelic loss	Lacks features of mitochondrial disease
7809	<i>MYO6</i>	chr6:75857131C> T, c.1258C>T; p.Arg420Cys	Deafness, nonsyndromic	Heterozygous missense	No evidence of deafness
7899	<i>MAP2</i>	chr2:209710227C >A, c.978C>A; Asn326Lys	Rett-like s. (preserved speech variant)	2q Contiguous gene deletion s.	Lacks Rett s.-like features
7886	<i>ITPR3</i>	chr6:33686219C> T, c.5834C>T; p.Thr1945Ile	Charcot-Marie-Tooth disease, demyelinating, type 1J	Heterozygous missense	Lacks features of Charcot- Marie-Tooth disease
7922	<i>GMPPB</i>	chr3:49723293G> A, c.220C>T;	Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A14	Biallelic loss	Excluded muscular dystrophy

		p.Arg74Ter			
7899	<i>CAPN3</i>	chr15:42411343G>C, c.2419G>C; p.Glu807Gln	Muscular dystrophy, limb-girdle, autosomal dominant 4	Heterozygous deletion	Excluded muscular dystrophy
7918	<i>BSG</i>	chr19:581510G>C, c.361G>C; p.Gly214Arg	Blood Group OK	Heterozygous missense	Not tested
7934	<i>ASH1L</i>	chr1:155479920G>A, c.2950C>T; p.Arg984Cys	Intellectual developmental disorder, autosomal dominant 52	Heterozygous missense	Cannot exclude intellectual disability
7803	<i>ADGRV1</i>	chr5:90811123C>A, c.2846C>A; p.Ala949Glu	Usher s: hearing loss and retinitis pigmentosa	Heterozygous loss (Febrile seizures)?, Biallelic loss (Usher s.)	No evidence of hearing or vision loss
7889	<i>CUL3</i>	chr2:224478199C>T, c.2175+1G>A; splice site lost	Pseudohypoaldosteronism, type IIE Neurodevelopmental disorder	Splice site variants (pseudohypoaldosteronism); Haploinsufficiency (Neurodevelopmental disorder)	Cannot exclude neurodevelopmental disorder
7901	<i>CNTNAP1</i>	chr17:42690144T>G, c.1792T>G; p.Phe598CVal	Hypomyelinating neuropathy, congenital, 3; Lethal congenital contracture s. 7	Biallelic loss	Lacks features of hypomyelinating neuropathy or contractures
7905	<i>DPYSL2</i>	chr8:26644084A>C, c.1103A>C; p.Lys332Thr	Intellectual disability and dysmorphic features(?)	Heterozygous missense	Cannot exclude evidence for intellectual disability or dysmorphic features
7918	<i>SCRIB</i>	chr8:143803792C>T, c.3026G>A; p.Arg1091Gln	Craniorachischisis	Haploinsufficiency	Lacks features of craniorachischisis
7944	<i>EP300</i>	chr22:41178614TCTC>T, c.6904_6907delTCTC;p.Leu2303Profs*49	Menke-Hennekam s. 2, Rubinstein-Taybi s. 2	Heterozygous missense	Excluded Menke-Hennekam or Rubinstein-Taybi s.
7540	<i>DHCR7</i>	chr11:71435428A>G, c.1375T>C; p.Trp427Arg	Smith-Lemli-Opitz s.	Biallelic loss	Lacks Smith-Lemli-Opitz s. features
6293	<i>TTC26</i>	chr7:139189388C>T, c.1228C>T; p.Arg410Trp,	Biliary, renal, neurologic, and skeletal s.	Biallelic loss	Lacks biliary or renal features
7542	<i>PLG</i>	chr6:160722467C>T, c.1156C>T; p.Arg386Ter	Angioedema, dysplasminogemia, plasminogen deficiency	Heterozygous gain of function or biallelic loss	Lacks features of angioedema
7525	<i>PCK2</i>	chr14:24103719C>T, c.1276C>T; p.Arg426Trp	PEPCK deficiency, mitochondrial	Biallelic loss	Lacks features of hypoglycemia or liver
7546	<i>LAMA3</i>	chr18:23912880A>T, c.3923A>T; p.Asp1308Val	Epidermolysis bullosa	Biallelic loss	Lacks features of epidermolysis bullosa
5686	<i>HECTD4</i>	chr12:112179032:G>C, c.11256C>G; p.Tyr3752Ter	Neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum (NEDSSC s.)	Biallelic loss	Excluded NEDSSC s.
5801	<i>TBXAS1</i>	chr7:140015737C>A, c.1244C>A; p.Ala415Glu	Ghosal hematodiaphyseal s.	biallelic loss	Excluded Ghosal hematodiaphyseal s.
5343	<i>PAX3</i>	chr2:222232203G>A, c.667C>T; p.Arg223Ter	Waardenburg s.	Haploinsufficiency	Meets clinical criteria for Waardenburg s.
5655	<i>MYBPC3</i>	chr11:47349785G>A, c.643C>T;	Cardiomyopathy, dilated, 1MM Cardiomyopathy, hypertrophic,	Haploinsufficiency or biallelic loss	Excluded heart defect

		p.Arg215Cys	4 Left ventricular noncompaction 10		
5560	<i>GRIA3</i>	chrX:123417592T>C, c.1691T>C; p.Ile564Thr	Intellectual developmental disorder, X-linked s., Wu type	Hemizygous mutations	Cannot exclude intellectual disability
5462	<i>CYB561</i>	chr17:63438215G T>G, c.13delA; Thr5Glnfs*8	Orthostatic hypotension 2	Biallelic loss	Lacks evidence for orthostasis
7218	<i>ZSWIM6</i>	chr5:61332835C>A, c.563C>A; p.Ala188Asp	Acromelic frontonasal dysostosis or NEDMAGA	Heterozygous p.R1163W or p.R913X missense	Excluded acromelic frontonasal dysostosis
6924	<i>VWA8</i>	chr13:41887322G>C, c.691C>G; p.Arg231Gly	Retinitis pigmentosa (?)	Heterozygous missense	Excluded retinitis pigmentosa
7164	<i>VPS50</i>	chr7:93291790G>T, c.1030G>T; p.Glu344Ter	Neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis	Biallelic loss	Excluded cholestasis
7073	<i>VPS13C</i>	chr15:61946374G>A, c.794C>T; p.Thr265Ile	Parkinson disease 23, autosomal recessive, early onset	Biallelic loss	Excluded Parkinson disease
7226	<i>TIAM1</i>	chr21:31146924T>G, c.545A>C; p.His182Pro	Neurodevelopmental disorder with language delay and seizures (NEDLDS)	Biallelic loss	Cannot exclude neurodevelopmental delay
6972	<i>SPEN</i>	chr1:15928231AC>A, c.1992delC; p.Gln665Lysfs*144	Radio-tartalgia s.	Haploinsufficiency	Cannot exclude Radio-tartalgia s.
7227	<i>POGZ</i>	chr1:151406022G>A, c.2827C>T; p.Arg943Cys	White-Sutton s.	Haploinsufficiency	Cannot exclude features of White-Sutton s.
7158	<i>PEX3</i>	chr6:143489224T>C, c.1120T>C; p.*374Arg (Loss of stop codon)	Peroxisome biogenesis disorder (Zellweger s.)	Biallelic loss	Excluded Zellweger s.
7223	<i>KDM5B</i>	chr1:202749126C>T, c.1700G>A; p.Arg567Gln	Intellectual developmental disorder, autosomal recessive 65	Biallelic loss	Cannot exclude intellectual disability
7013	<i>IRS1</i>	chr2:226796947G>GC, c.1791_1792insG;p.His598Alafs*13	Type 2 diabetes mellitus, susceptibility to	Haploinsufficiency	Excluded type 2 diabetes
7217	<i>IRS1</i>	chr2:226796947G>GC, c.1791_1792insG;p.His598Alafs*13	Type 2 diabetes mellitus, susceptibility to	Haploinsufficiency	Excluded type 2 diabetes
7191	<i>GRHL2</i>	chr8:101619557T>C; c.1448T>C; p.Cys373Arg	Corneal dystrophy, Deafness, autosomal dominant 28, Ectodermal dysplasia/short	Heterozygous (corneal dystrophy, deafness); homozygous (ectodermal)	Excluded corneal dystrophy, deafness or ectodermal dysplasia

			stature s.	dysplasia)	
7119	<i>FREM1</i>	chr9:14801790T>G, c.3556A>C; p.Ser1186Arg	Bifid nose with or without anorectal and renal anomalies; Manitoba oculotrigoanal s.; Trigonocephaly type 2	Biallelic loss; Haploinsufficiency; (Trigonocephaly only)	Cannot exclude trigonocephaly
6985	<i>FEM1C</i>	chr5:115524327A> G, c.1835T>C; p.Phe612Ser	Developmental delay, pyramidal signs, and limb ataxia (?)	Heterozygous missense	Cannot exclude developmental delay
7202	<i>DCX</i>	chrX:111401096T> C, c.599A>G; p.Asn200Ser	Subcortical laminar heterotopia	Heterozygous missense	Cannot exclude features of subcortical laminar heterotopia
7002	<i>DAG1</i>	chr3:49531270G>G A, c.759_760insA; p.Asn254Lysfs*20	Muscular dystrophy- dystroglycanopathy	Biallelic loss	Lacks features of muscular dystrophy
7071	<i>CLTC</i>	chr17:59666977G> A, c.2140G>A; p.Gly714Ser	Intellectual developmental disorder, autosomal dominant 56	Haploinsufficiency	Cannot exclude intellectual disability
6966	<i>BRAT1</i>	chr7:2543876C>T, c.369G>A; p.Trp123Ter	Neurodevelopmental disorder with cerebellar atrophy and with or without seizures; rigidity and multifocal seizure s.	Biallelic loss	Lacks features of cerebellar atrophy or seizures
6950	<i>ADRA2B</i>	chr2:96115933C>G , c.217G>C; p.Glu73Gln	Epilepsy, familial adult myoclonic	Heterozygous in frame insertion/deletion	Cannot exclude myoclonic epilepsy
7123	<i>LEMD3</i>	chr12:65169828GC CGCGGGACCAGC >G, c.233_245delCCGC GGGACCAGC; p.Arg78Glyfs*101	Buschke-Ollendorff s. Osteopoikilosis with or without melorheostosis	Heterozygous deletion/insertion, duplication, frameshift, missense	Cannot exclude Buschke- Ollendorff s.
7155	<i>TBXT</i>	chr6:166160836, c.1034+1G>C Loss of splice site	Sacral agenesis with vertebral anomalies	Biallelic loss	Lacks features of sacral agenesis
7157	<i>UBIAD1</i>	chr1:11285729C>G , c.258C>G; p.Ile86Met	Corneal dystrophy, Schnyder type	Haploinsufficiency	Lacks features of corneal dystrophy
5943	<i>SQOR</i>	chr15:45661973A> G, c.253A>G; p.Ile85Val	Sulfide quinone oxidoreductase deficiency	Biallelic loss	Lacks features of sulfide:quinone oxidoreductase deficiency
5980	<i>SEC31A</i>	chr4:82854963:TC> T, c.1146delG; p.Trp382Ter	Halperin-Birk s.	Biallelic loss	Excluded Halperin-Birk s.
6686	<i>KRT83</i>	chr12:52314788C> A, c.1325G>T; p.Cys442Phe	Erythrokeratoderma variabilis et progressiva 5	Biallelic loss (Erythrokeratoderma); Haploinsufficiency (Monilethrix)	Lacks skin defects

6692	<i>HR</i>	chr8:22120753C>A, c.2573G>T; p.Gly858Val	Alopecia universalis Atrichia with papular lesions	Biallelic loss	Lacks features of alopecia universalis
6707	<i>DNAH11</i>	chr7:21801213A>C, c.10310A>C; p.Glu3368Ala	Ciliary dyskinesia, primary, 7, with or without situs inversus	Biallelic loss	Lacks features of ciliary dyskinesia or situs inversus
8867	<i>PREPL</i>	chr2:44339179G>C , c.670C>G; p.Leu224Val	Myasthenic s, congenital, 22	Biallelic loss	Lacks features of myasthenia
8828	<i>PAX3</i>	chr2:222297081G >T, c.218C>A; p.Ser73Ter	Waardenburg s.	Haploinsufficiency	Meets criteria for Waardenburg s.
8828	<i>INF2</i>	chr14:104713537 C>T, c.2971C>T, p.Arg991Trp	Charcot-Marie-Tooth disease, dominant intermediate E with Glomerulosclerosis, focal segmental, 5	Haploinsufficiency	Excluded Charcot-Marie-Tooth or glomerulosclerosis
8861	<i>GRHL3</i>	chr1:24342238, c.892C>T; p.Arg298Cys	van der Woude s. type 2	Haploinsufficiency	Cannot exclude van der Woude s. type 2

1446 **Supplementary Table 1. Phenotypic expansion of MM genes with DNM displaying**
1447 **syndrome and/or non syndrome disease features other than MM.** Column 1: Family
1448 number, Column 2: mutated gene, Column3: Mutation identified for that gene and patient
1449 in our cohort, Column 4: Relevant OMIM entry for each gene. Column 5: type of
1450 mutation reported in OMIM leading to phenotype. Column 6: Evidence for or against
1451 concordance with the OMIM phenotype. Genomic coordinates are in hg38. s.: syndrome,
1452 question mark (?): association remains uncertain according to OMIM.

1453 **Supplementary Notes**

1454

1455 ***Power calculations for effect size***

1456 To determine the adequate cohort size for identification of recurrently mutated genes in
1457 MM, we developed a computational model and power calculations to estimate effect
1458 size^{77,78}. We first determined that with a sample size of 350 trios, observing such
1459 recurrence in two families would be significant genome-wide, with P value = 0.003, and
1460 from this calculated the false-discovery rate (FDR), assuming a baseline DNMM rate
1461 among the ~20,000 human genes (**Extended Data Fig. 1** gray dashed line). Then,
1462 leveraging data from a small NTD WES study in which DNMM LOF mutations were
1463 identified in 20% of subjects, 34, and estimating that about 0.4% (i.e. 80/20,000) of gene
1464 knockouts in mouse show a MM-like phenotype, we estimate that there are 50–100 MM
1465 disease genes (k) to be discovered. Borrowing from previous literature^{13,21,79}, we
1466 anticipate that LOF variants will be enriched in patients vs. controls with a v ratio
1467 between 1.5 and 2.5. We ran 10,000 iterations to estimate the number of genes we will
1468 discover for various cohort sizes ranging from 100–1000 trios (**Extended Data Fig. 1**).
1469 For instance, with a cohort size of 400, if there are 50 genes to discover (i.e. $k = 50$) and
1470 with 2.5 times as many LOF variants in patients vs. control (i.e. $v = 2.5$), we expect ~16
1471 recurrently mutated genes to emerge. For the same cohort, if $k = 100$ and $v = 1.5$, we
1472 expect to discover ~2 recurrently mutated genes. Given the recurrence found in the cohort
1473 of 43 trios¹⁵, and our preliminary data, we anticipated our results will fall between these
1474 two scenarios. Notably, this model predicts that with 800 MM trios sequenced as we
1475 propose here, we expect to discover ~5–10 recurrently mutated MM genes.

1476

1477 ***Reproducible prediction of D-Mis-HC***

1478 To validate the high confidence damaging missense variant (D-Mis-HC) that was
1479 originally called by MetaSVM, we also applied MetaLR and REVEL to the DNMMs. The
1480 D-Mis-HC was highly reproducible with the two additional annotation tools with
1481 recommended thresholds, MetaLR score > 0.5 and REVEL > 0.75 (**Extended Data Fig.**
1482 **16c-16d**).

1483

1484 ***Parents' age of conception comparison***

1485 To confirm if the excessive DNMM burden in MM compared to controls are independent
1486 from the ages of parents at the time of conception, we gathered dates of births from
1487 probands, fathers, and mothers. Trios that were able to track all information from three
1488 family members (MM: 79, control: 683) were collected, to compare the ages of
1489 conception of father and mother, with Wilcoxon rank-sum test. (two-sided). We could
1490 clearly confirm that both the ages of mothers and fathers in the MM cohort were
1491 significantly lower than those of controls (**Extended Data Fig. 2a**). Although the rate of
1492 de novo variants is known to be highly correlated with the age of parents, the excessive
1493 burden observed in our study is not derived from the difference of fathers' and mothers'
1494 age distribution.

1495

1496 ***WGS evaluation for DNMMs contributing to MM risk***

1497 From 101 additional trios and 1 quartet, we observed comparable de novo SNV and Indel
1498 rates with WGS data (**Extended Data Table 1**). Among them, 13 LGD and 39 D-Mis

1499 coding DNMs were observed. Also, 9 splicing disrupting variants (SpliceAI maximum
1500 delta score larger than 0.9) and 41 possible pathogenic noncoding DNMs (GREEN-
1501 VARAN level 4) were collected. However, there was no recurrent gene mutated within
1502 the WGS cohorts (see **Supplementary Data** for the full list of DNMs in WGS). Instead,
1503 three overlapped with damaging (LGD+D-Mis) DNMs with WES data were revealed: a
1504 stop-gain in KDM1A, a splice donor gain in ITPR3, and a variant in GRHL2 enhancer.
1505 We could find four de novo CNVs (> 100 kb) in WGS trios, four de novo deletions and
1506 duplications were observed (**Extended Data Table 2**). The large CNVs were confirmed
1507 with the parents' sequence data (**Extended Data Fig. 3b**) and the duplicated or deleted
1508 regions were not recurrent. No de novo translocation or inversion was observed.

1509

1510 ***Multiplexed Error Robust In Situ Hybridization (MERFISH) spatial transcriptomic*** 1511 ***expression pattern of a subset of DNM genes***

1512 We conducted Multiplexed Error Robust Fluorescent In Situ Hybridization (MERFISH)
1513 on the Vizgen platform using the methodology as described in Methods⁶⁴. We segmented
1514 a total of 352,729 cells with uniform transcript density using cell segmentation. A subset
1515 of cells was excluded due to outlier cell volume ($n = 9,922$) or transcript density ($n =$
1516 $21,319$), with the remaining cells divided into 63 distinct clusters based on gene
1517 expression using the Leiden algorithm, stratifying into 7 major cell types (Neuron, Neural
1518 crest, Neural Progenitor, Dorsal Root Ganglia, Pre epithelial to mesenchymal transition
1519 neural Crest progenitor, Mesoderm and Blood) in mouse E9.5 parasagittal sections. Cell
1520 types were defined by expression of marker genes selected based on previously published
1521 single cell transcriptomic studies⁶⁵⁻⁶⁷, employing ScType⁸⁰ for unbiased cell typing from
1522 marker gene expression. Approximately 14% cells were flagged as 'indeterminate' type
1523 that could not be clearly categorized, likely due either to a state of transitioning between
1524 cell types or lacking expression of marker genes. We selected 36 DNM genes identified
1525 in MM subjects for multiplex spatial co-expression analysis (**Extended Data Fig. 4**).
1526 Percentage of gene expression vs cell type revealed that most of the candidate DNM
1527 genes show expression in multiple cell types during neural tube closure. There were some
1528 genes like *Rnd2* and *Add2* that were expressed predominantly in neural cells, *Celsr1* in
1529 neural progenitor, *Stab1* in pre-EMT-neural precursor cells, *Opalin* expressed in
1530 predominantly in blood (**Extended Data Fig. 5**).

1531

1532 ***Additional evidence for role of functionally implicated DNM genes in NTDs***

1533 The DNM genes in which the DNM mutation impairs protein function showed additional
1534 prior evidence that may suggest a role in human NTDs. TIAM1, which promotes actin
1535 assembly via the Arp2/3 complex⁸¹, is essential for neural tube closure in mice⁸², but not
1536 previously implicated in human NTD. TNK2, also known as ACK1 is a kinase associated
1537 with CDC42 that controls cellular protrusions associated with spinal neurulation in
1538 mouse³². VWA8 is a mitochondrial matrix-targeting ATPase, and notably mitochondrial
1539 dysfunction is implicated in both genetic and environmental murine models of NTD^{49,83}.

1540

1541 ***Clinical phenotypes of patients compared to OMIM***

1542 We assessed possible connections between DNM genes and associated OMIM
1543 phenotypes by recontacting subjects to inquire about clinical features listed in OMIM but
1544 possibly not described at the time of enrollment into our study. Resources used were

1545 Online Mendelian Inheritance in Man (OMIM), ClinVar, and PubMed. Out of the 192
1546 DNMs found in our cohort 82 were found to have other OMIM phenotypes (43.8%).
1547 Genes found to have other OMIM phenotypes in individual families/subjects were further
1548 reviewed regarding the type of mutation compared with those reported in the clinical
1549 literature and compared with clinical status (**Supplementary Table 1**). Information
1550 available at the time of enrollment was used for clinical correlation along with follow up
1551 with the families via telephone or zoom to specifically inquire about features related to
1552 the published OMIM phenotypes. For some subjects like 6695, the de novo mutation
1553 occurred in a gene showing only recessive inheritance (*TIMM50*), so it was not surprising
1554 that the MM subject carrying a DNM in the gene did not report features of the OMIM
1555 entry. But for other subjects like 6313, the DNM occurred in a gene with the same or
1556 similar zygosity, and the patient showed features that cannot be distinguished from the
1557 reported OMIM entry, in this case Coffin-Siris features (i.e. developmental disability,
1558 abnormalities of the fifth (pinky) fingers or toes, and characteristic facial features),
1559 suggesting MM may be a phenotypic expansion of this syndrome.

1560

1561 ***Estimation of number of genes in DNM contributing to MM risk***

1562 The estimation was based on previous publication¹⁴. Briefly, the total number of risk-
1563 associated genes (C) is calculated with the number of observed risk-associated mutations
1564 ($d = 192$) and recurrent mutations ($r = 5$, *PAX3*, *IRS1*, *ZSWIM6*, *BRSK2*, and *VWA8*).
1565 Since 28.26% of the damaging DNMs (LGD + D-Mis) are contributing to the MM risk, d
1566 and r were normalized as 54.26 and 1.41. The number of observed risk-associated genes
1567 is c and c_1 refers to the number of genes mutated once and the probability of a newly
1568 added mutation hitting a previously mutated gene (μ) could be calculated as follows.
1569 Considering the variation in effect size of individual DNMs are assumed to be 1 to
1570 minimize underestimation of set size, C could be estimated as 2,021 genes.

1571

1572

$$c = d - r$$

1573

$$c_1 = d - (2 \times r)$$

1574

$$\mu = 1 - c_1/d$$

1575

$$C = \frac{C}{\mu} + (g^2 \times d \times (1 - \mu)/\mu$$

1576